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Zusammenfassung 
Die Invasion von Leukozyten in das zentrale Nervensystem (ZNS) ist ein wesentlicher 
Bestandteil bei der Pathogenese von Hirnverletzungen sowie akuten und chronischen 
Entzündungsvorgängen im Gehirn. Bisher ist nur wenig über gegenregulatorische 
Mechanismen der lokalen, angeborenen Immunzellen bekannt, die bei Entzündungen im 
ZNS eine Rolle spielen können. Mikrogliazellen, die überwiegende Population 
immunkompetenter Zellen des ZNS, stellen die erste Verteidigungslinie im Hinblick auf 
Verletzungen und Erkrankungen des Gehirns dar. Im Rahmen vieler neurodegenerativer 
Erkrankungen wird die Zerstörung von Neuronen, aber auch die kollaterale 
Gewebsschädigung auf die Aktivierung der Mikrogliazellen zurückgeführt. 
Die vorliegende Arbeit beschreibt erstmalig einen regulatorischen Aktivierungszustand der 
Mikroglia (CD40dimCD86dimIL-10high), der zur Induktion regulatorischer Foxp3+ T-Zellen (Treg) 
führt. Die Stabilität und funktionelle Aktivität Mikroglia-induzierter regulatorischer T-Zellen 
konnte sowohl in vitro als auch in vivo gezeigt werden. In vitro inhibierten sie die Proliferation 
antigen-spezifischer Effektorzellen, in vivo führte ein adoptiver Transfer der regulatorischen 
T-Zellen zur Abmilderung des Krankheitsverlaufes experimentell induzierter, autoimmuner 
Enzephalomyelitis (EAE). Mikrogliazellen unterstützten sowohl die Proliferation bereits 
ausgebildeter regulatorischer T-Zellen als auch deren Differenzierung aus naiven T-Zellen. 
Die Induktion regulatorischer T-Zellen durch Mikroglia war Major Histocompatibility Complex 
(MHC)-II-abhängig und antigenspezifisch. Für Untersuchungen zur in vivo Relevanz wurden 
MHC-II-chimäre Mäuse generiert und eine Läsion im entorhinalen Kortex gesetzt. Fehlte 
MHC-II in ZNS-residenten Zellen, wurden weniger regulatorische T-Zellen pro Leukozyt in 
die lädierten Hemispheren rekrutiert. 
Zusammenfassend demonstrieren diese Ergebnisse das Modulationspotential von 
Mikrogliazellen auf die CD4+ T-Zellantwort. Die Mikroglia-induzierte Differenzierung und 
Proliferation von Foxp3+ regulatorischen T-Zellen ist ein möglicher Mechanismus der 
Regulation von Entzündungsvorgängen im ZNS durch Mikrogliazellen. 
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Summary 
The invasion of leukocytes into the central nervous system (CNS) is a key event in the 
pathogenesis of CNS injury and acute or chronic inflammatory neurological diseases. 
However, regulatory mechanisms of local innate immune responses that limit CNS 
inflammation are only poorly understood. Microglia are the predominant innate immune cells 
of the brain and present the first line of defence in CNS injury or disease. In the context of 
neurodegenerative disease, microglia activation accounts for collateral tissue damage and 
neurodestruction. 
This thesis for the first time describes a regulatory microglia phenotype 
(MHCII+CD40dimCD86dimIL-10high) that induced a strong Foxp3+ regulatory T cell (Treg) 
response. Microglia-induced Treg cells were stable and functionally active in vitro by 
inhibiting antigen-specific proliferation of effector T cells and in vivo, by attenuating 
experimental autoimmune encephalomyelitis (EAE) disease course after adoptive transfer. 
The data also suggested that regulatory microglia can mediate both, proliferation of Foxp3+ 
Treg cells and de novo differentiation from naive CD4+ T cells. Microglia-mediated Treg 
induction was proven to be MHCII and antigen-dependent. Using entorhinal cortex lesion 
(ECL) as a brain injury mouse model, diminished Foxp3+ Treg cell recruitment per infiltrated 
leukocyte in chimeric mice lacking MHCII specifically in the CNS was demonstrated, 
indicating in vivo relevance of antigen presentation by brain resident cells. 
Taken together, these findings demonstrate that microglial cells can directly modulate CD4+ 
T cell responses by regulating molecule levels for efficient antigen presentation and levels of 
secreted cytokines and chemokines. Microglia-mediated differentiation and proliferation of 
Foxp3+ Treg cells can be one of the mechanisms how microglia contribute to local immune 
homeostasis and limit CNS inflammation. 
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1 Introduction 
Experiments showing foreign graft acceptance had once formed the idea of the central 
nervous system (CNS) as an organ ignored by the immune system. Being isolated from the 
immune system by the blood-brain barrier (BBB) and by the blood–cerebrospinal fluid barrier 
(BCSFB) and lacking conventional lymphatics, the CNS compartment was considered as an 
immune privileged site. Minimal major histocompatibility complex (MHC) class II expression 
on parenchymal cells, low cytokine and chemokine levels and low T cell numbers in healthy 
brains supported this idea1. However, increasing evidence suggests a new concept of the 
interplay between the immune and the central nervous system and eventually led to revision 
of this long-standing concept of the CNS immune privilege. 
The BBB is a complex structure consisting of specialized capillary endothelial cells, basal 
laminas and adjacent pericytes, astrocytes, and microglia forming the functional 
neurovascular unit. CNS endothelial cells differ from non-CNS endothelial cells by forming 
tight junctions and a deficiency in transcellular transport systems, e.g. pinocytotic vesicles. 
As a result, the BBB is a physical, metabolic and immunological barrier limiting the access of 
circulating blood cells and soluble factors, except of those that are small and lipophillic2. 
Pathological conditions that affect BBB integrity and allow immune cell infiltration are 
Alzheimer’s and Parkinson’s disease (BBB disruption), inflammation (increased BBB 
permeability), multiple sclerosis (disruption of tight junctions), stroke (BBB disruption) or brain 
trauma (BBB breakdown)3. Contrary to historical thinking, latest studies show, that even 
under non-pathological conditions, peripheral immune cells are able to transmigrate across 
the intact BBB4–6. CNS immune surveillance is now considered a normal ongoing 
physiological process7. 
In the healthy state, the local CNS milieu is characterized by very low levels of 
immunologically relevant molecules and, in marked contrast to the historical view of 
immunologic incompetence, this suppressed CNS microenvironment is actively maintained 
by functional neurons. In turn, neurodegenerative pathology is often accompanied by 
inflammatory activity, such as activation of brain resident immune cells, up-regulation of 
cytokines and chemokines and the recruitment of leucocytes into the brain8. Compared to 
peripheral tissues, the CNS is less efficiently drained by lymphatic vasculature. However, T 
cells specific for brain antigens are found in the normal lymphatic T cell repertoire9,10 and 
several outflow pathways connecting the CNS with lymphatics have been described11 
allowing the transport of e.g. brain antigens to CNS draining lymph nodes. 
Therefore, the concept of the CNS as immunologically inert and immunologically separated 
from the peripheral immune system has to be rejected and replaced by the notion of a 
dynamically interacting and complex relationship between the CNS and the immune system. 
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1.2 Cells and microenvironment of the brain 
The CNS is composed of two kinds of specialized cells: neurons and glial cells. Glial cells, 
known as supporting cells, vastly outnumber neurons in the brain, indicating how much 
support a neuron needs to process and transmit information through the nervous system. 
Besides ensuring structural integrity, glial cells provide metabolic functions, assist in repair 
and maintenance of the nervous system, clear waste or are involved in key developmental 
processes, to name but a few of their functions. Astrocytes, oligodendrocytes, and microglia 
are the three types of glial cells that support the health of neurons in the CNS, the latter 
being the focus of this thesis. 
Oligodendrocytes and astrocytes constitute macroglia16. Astrocytes, which are now thought 
to be involved in almost all aspects of brain function17, were discovered to even release 
gliotransmitters, thereby facilitating neuronal communication. The principle function of 
oligodendrocytes is to form the myelin sheath maintaining long-term axonal integrity18. 
Microglia, the resident innate immune cells of the brain, are the smallest of the supporting 
glial cells and found throughout the CNS. 
The healthy CNS is often termed immunosuppressive, referring to the hostile environment 
created for infiltrating cells of the adaptive immune system19. Besides low expression of MHC 
class II and pro-inflammatory cytokines, the neuronal microenvironment is tightly controlled 
and modulated by immunosuppressive cytokines (TGF-β, IL-1) and neurotrophins. Immuno-
suppressive factors produced by neurons such as neurotrophin-3 (NT-3), nerve growth factor 
(NGF) and brain-derived neurotrophic factor (BDNF) are thought to limit the activation of 
astrocytes and microglia20. 
1.3 Microglia – Immune sentinels of the CNS 
Microglia are the predominant innate immune cells in the brain and therefore present the first 
line of immune defense whenever there is injury or disease21,22. Depending on the specific 
region of the CNS, microglia constitute about 5-20% of total glial cells and vary in density and 
morphology23,24. Compact microglial cells with short, thick processes are found in 
circumventricular organs, longitudinally branched cells in the fibre tracts and radially 
branched cells in all areas of the grey matter23. The tissue of origin and the specific lineage 
of microglia and their progenitors was a subject of debate for decades. In contrast to 
neuroectoderm-derived neurons, astrocytes and oligodendrocytes, microglial progenitors are 
now thought to arise from peripheral mesodermal (myeloid) tissue25. However, whether 
circulating monocytes and/or myeloid progenitor cells contribute to the repopulation of 
steady-state parenchymal microglia in the adult CNS is still an unsolved question24. 
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In the healthy brain, microglia are continually palpating and surveying their local 
environment26, exhibiting a typical ramified morphology with small somata and fine processes 
with secondary and tertiary branches (Fig. 1.2). In this appearance, microglia exhibit an 
actively repressed or down-regulated phenotype, clearly distinct from other macrophage 
populations, which is usually termed “resting” state. In response to invading pathogens, 
inflammation, trauma, ischemia, neurodegeneration or altered neuronal activity, microglia 
rapidly undergo changes resulting in diverse functional phenotypes and amoeboid 
morphology (reactive microgliosis). Depending on the stimulus confronted with, activated 
microglia accumulate at sites of tissue damage, up-regulate various cell surface antigens, 
produce cytokines and chemokines or increase phagocytosis, as described in more detail in 
the following section. This rapid shift from a resting to an activated state, even in response to 
poor stimuli, is a hallmark of microglial cells, which are therefore termed “immune sentinels” 
of the CNS. 
 
Fig. 1.2 Microglia activation. 
Upon stranger (invading pathogens) or danger (trauma, neurodegeneration, ischemia, inflammation or altered 
neuroactivity) signals microglia undergo a characteristic morphological change. Resting microglia, characterized 
by ramified morphology with fine processes, participate in immune surveillance and display an 
immunmodulatory down-regulated phenotype. Activated microglia aquire amoeboid morphology and participate 
in innate and adaptive immune responses (by phagocytosis, cytokine/chemokine production and antigen 
presentation) or mediate neurotoxicity by release of neurotoxic factors. 
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Upon activation, microglia participate in both innate and adaptive immune responses24 
similar to peripheral macrophages. Activated microglial cells share several phenotypical and 
functional characteristics of circulating and tissue-resident macrophages, leading to the 
common designation: resident macrophages of the brain. Indeed, there is currently no cell 
surface marker available that reliably distinguishes brain resident microglia from peripheral 
macrophages. Particularly under pathological conditions associated with leukocyte entry into 
the CNS, a clear discrimination between brain resident microglia and brain infiltrating 
phagocytic cells remains difficult. The integrins CD11a and CD11b, LPS co-receptor CD14, 
leukocyte common antigen (CD45) and F4/80 (EMR1) are common cell surface markers of 
both, murine microglia and macrophages. For flow cytometry, the combination of CD45 and 
CD11b is often used to roughly distinguish between microglia (CD11b+CD45dim) and 
macrophages (CD11b+CD45high)27. In turn, many antigens typically found on other 
macrophage populations, such as MHC class II, ICAM-1 or CD40, are missing or expressed 
at low levels on microglia of the healthy CNS1. 
1.3.1 Microglia in health and disease 
The term “microglial activation” implies that resting microglia are without functional 
importance. However, microglia of the healthy CNS constantly monitor their environment and 
adjacent cells using their fine, motile processes28. The term “resting” state refers to their 
immunomodulatory down-regulated phenotype. Distinct from other macrophage populations, 
resting microglia exhibit only low levels of MHC II and co-stimulatory molecules and secrete 
themselves immunosuppressive factors (TGF-β, BDNF, NGF)29. Under steady-state 
conditions their down-regulated phenotype is actively maintained by functional neurons, e.g. 
cell-cell contact (CD47-CD172, CD200-CD200R, CD22-CD45)30 and secreted factors 
(CX3CL1)31. In addition, astrocytes produce immunosuppressive IL-4, IL-10 and TGF-β32,33. 
Performing continuous surveillance of their environment, microglia are key players in 
maintaining CNS homeostasis. Any disturbance in the CNS, changes in structural integrity, 
invasion of pathogens or alterations in microenvironment, can evoke a microglial response. 
“Microglial activation” is a term widely used in the context of CNS inflammation or 
neurodegenerative disease − most often without further definition. However, recent studies 
describe a phenotypic and functional plasticity of microglia that is dynamic and finely graded. 
The concept of microglia activation therefore needs to be revised, assigning a clear definition 
to the respective phenotypes. In the following, different microglia activation phenotypes will 
be introduced in the context of neurodegenerative disease or CNS injury. 
Infections of the CNS result in innate and adaptive immune responses initiated by microglial 
cells. Microglia sense invading pathogens (e.g. bacteria, viruses and protozoa) and related 
particles by Toll-like receptors (TLRs), a major family of pattern recognition receptors. The 
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entire complement of TLR 1-9 are expressed by microglia34. Following pathogen recognition, 
microglia release pro-inflammatory mediators, such as TNF-α, IFN-β, IL-1β or IL-634, and 
chemokines (CXCL-10, MCP-1) to recruit cells of the adaptive immune system (e.g. T 
lymphocytes and monocytes) to the site of infection for pathogen clearance35. It is proposed 
that the microglia-mediated defense against CNS invading pathogens leads to collateral 
tissue damage and neurodegeneration through secretion of neurotoxic factors (NO, TNF-α) 
and leukocytes recruitment36. 
The role of microglia in Alzheimer’s Disease (AD), a progressive, irreversible 
neurodegenerative disease, is discussed controversially. Activated microglia are closely 
associated with β-amyloid (Aβ) plaques, which are, together with neurofibrillary tangles, a 
histopathological hallmark in AD brains. Microglia can respond to amyloid-β deposition by up-
regulating phagocytic activities (e.g. expression of scavenger receptors) resulting in Aβ 
clearance, but at the same time, they can locally secrete neurotoxic substances 
(inflammatory cytokines, reactive oxygen species, proteinases, and complement proteins) 
leading to tissue damage of surrounding areas37,38. In addition, several groups showed that 
activated microglia that co-localized with Aβ plaques also up-regulated MHCII39,40. 
Immunotherapy of Alzheimer’s disease therefore focuses on activating microglia to decrease 
the amyloid-β load without inducing neurotoxic inflammation that occurs secondary to 
amyloid-β deposition37. 
Multiple Sclerosis (MS) is a heterogeneous autoimmune disease that is characterized by 
severe CNS inflammation, demyelination and axonal loss resulting in a variety of 
neurological symptoms41,42. Autoreactive, myelin-specific T cells of the CD4 T cell lineage, 
mainly Th1 and Th17 cells, are thought to mediate MS pathology by either promoting the 
accumulation of inflammatory immune cells (typical white matter lesions) or directly 
damaging oligodendrocytes and neuronal cells. It is generally thought that Th1 and also 
Th17 cells, directed against myelin antigens such as proteolipid protein (PLP), myelin basic 
protein (MBP), myelin associated protein (MAG) or myelin oligodendrocyte glycoprotein 
(MOG), enter the brain were they re-encounter CNS antigens presented by microglia and/or 
perivascular macrophages and initiate a destructive inflammatory cascade43,44. Experimental 
autoimmune encephalomyelitis (EAE) is a widely used animal model of MS. EAE can be 
either induced actively by immunization with myelin antigens or peptides (MOG, PLP, MBP) 
in complete Freund’s adjuvant, or passively by adoptive transfer of activated 
encephalitogenic T cells isolated from immunized animals45. EAE studies in MHC-
mismatched bone marrow chimeric mice demonstrated that brain resident microglia up-
regulate CD45, MHCII, CD86, CD40 and CD11c as a sign of activation and undergo 
proliferation very early in disease progression46. Activated microglial cells not only co-localize 
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with infiltrating leukocytes in inflammatory lesions46, but are also found throughout the brain 
during disease progression47,48. Whether myelin-antigen presenting microglia migrate out of 
the brain and reach brain draining cervical or deep cervical lymph nodes is still 
controversially discussed. 
Moreover, synaptic pathology was shown to correlate with the presence of activated 
microglia47. This is supported by a study showing that inactivation of microglia, using CD11b-
HSVTK mice, inhibits EAE, suggesting that the microglia compartment provides a potential 
therapeutic target49. In sum, microglia activation towards antigen presentation is generally 
thought to contribute to MS pathology. 
Within a few hours after an ischemic stroke analysis of blood, spleen and thymus show 
marked and long-lasting lymphopenia together with impaired cellular immune functions as 
part of a stroke-induced immunodeficiency syndrome (SIID)50. Possible explanations for SIID 
involve elevated lymphocyte apoptosis in spleen and thymus, a shift to an anti-inflammatory 
cytokine response in the peripheral organs or increased frequencies of regulatory T cells50. In 
addition, brain ischemia and resulting cell death induce hyperactivity of the sympathetic 
nervous system and the hypothalamic–pituitary–adrenal (HPA) axis, thereby increasing the 
risk of infectious complications51. The local immune responses to stroke include the release 
of endogenous molecules termed damage-associated molecular patterns (DAMPs) from 
dying cells, the activation of microglia and astrocytes and the recruitment of leukocytes52. 
Microglial cells rapidly migrate to the affected site, undergo proliferation and release 
neurotoxic mediators such as superoxide, nitric oxide (NO), proteases (metalloproteases 
MMP-3, MMP-9) and proinflammatory cytokines (TNFα, IL-1β, IL-6)53. Whether or how 
microglia directly contribute to the systemic immunodepression after stroke e.g. by secreting 
mediators that enter the systemic circulation, is still a matter of debate. Besides the fact that 
post-ischemic inflammation exacerbates ischemic injury there is emerging evidence that 
some aspects of immune responses might promote tissue repair and recovery52. 
CNS injury mostly results in axonal degeneration, cell death, destruction of the BBB, massive 
release of self-antigens and expansion of myelin-specific T cells in local lymph nodes54. In 
experimental lesion models such as entorhinal cortex lesion (ECL), facial nerve crush, spinal 
cord injury (SCI) or traumatic brain injury (TBI), microglia were shown to be activated within 
one hour after injury55 and remain activated up to one or two weeks after injury2,56. CNS 
tissue damage induces microglia to migrate to the lesion site, increase in number57, 
phagocytose neuronal debris and present antigens in a MHCII dependent way58. In addition 
to general leukocyte recruitment (e.g. neutrophils, monocytes), myelin-specific lymphocytes 
expand in draining lymph-nodes59, subsequently invade regions of degeneration58,60 and 
mediate secondary white matter damage. However, brain injury does not evoke destructive 
immunity, such as observed in MS or EAE. These findings indicate that inflammation in 
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regions of degeneration is tightly regulated and controlled, implying active maintenance of 
immune tolerance54. 
In sum, microglia contribute to both innate and adaptive immunity. Microglial cells can 
migrate to regions of tissue damage, undergo proliferation, increase phagocytic activity to 
clear debris, up-regulate molecules for effective antigen presentation, secrete cytokines and 
chemokines in order to regulate recruitment of leukocytes to the CNS or release reactive 
oxygen species and proteases (Fig. 1.2). In the focus of neurodegenerative disease the 
neurodestructive role of activated microglia has been widely accepted, considering microglia 
as promising target for anti-inflammatory treatment. The exact mechanisms by which 
activated microglia kill neurons are complex and not fully understood, but appear to involve 
expression of NADPH oxidase (NOX), inducible NO synthase (iNOS) and microglial 
phagocytosis of neurons61. Nevertheless, recent work also highlights neuroprotective aspects 
of microglial activation62,63, including secretion of protective cytokines (TGF-β, IL-10) or 
increased phagocytosis of debris64. This thesis focuses on potentially beneficial aspects of 
microglial activation by investigating the regulation of microglia antigen presenting capacities 
that balance between inflammatory (pathogenic) or anti-inflammatory (protective) T cell 
responses. 
1.4 Microglia – CD4+ T cell interaction 
This thesis aims to understand the interaction of microglia and CD4+ T cells. Therefore the 
activation by antigen, formation of distinct lineage and classification of the latter should be 
briefly explained at this point. 
Activation of naive CD4+ T lymphocytes occurs in secondary lymphoid organs (lymph nodes, 
spleen, Peyer’s patches, tonsils) during their recirculation. Activation of naive CD4+ T 
lymphocytes requires recognition of their specific antigen bound to MHCII molecules by the T 
cell receptor (TCR - MHCII-Ag, signal 1) and co-stimulators, such as B7-1 and B7-2 that are 
expressed on activated antigen-presenting cells (signal 2). Signals 1 and 2 are provided by 
professional antigen presenting cells (APC), such as dendritic cells, macrophages and B 
cells, which efficiently internalize antigen, migrate to secondary lymphoid organs and present 
antigens via MHCII molecules. Signal 3, the polarization signal, is mediated by soluble and 
membrane bound factors, such as interleukines (IL-12, IL-4) or chemokine ligands (e.g. 
CCL2)65. Th1 cells differentiate in the presence of IL-12, produce mainly IFNγ and IL-2, and 
are involved in cell-mediated immunity. Th2 cells develop in the presence of IL-4, secrete 
primarily IL-4, IL-5 and IL-13 and contribute to humoral immunity. On the transcriptional level 
T-bet and STAT4 transcription factors promote Th1 cell fate, whereas GATA3 and STAT6 
govern Th2 cell polarization. Upon activation, effector T cells migrate to any site of infection 
or inflammation, where they re-encounter their specific antigen. 
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Like naive CD4+ T cells, naturally arising CD4+ regulatory T cells (nTreg) emerge from the 
thymus, express the transcription factor Foxp3, and are engaged in suppressing immune 
responses towards self and non-self antigens. Unlike the majority of thymus-derived naive 
CD4+ T cells, nTreg cells are already functionally mature and antigen-primed66. Naive CD4+ T 
cells can also differentiate into Foxp3+ regulatory T cells in peripheral lymphoid tissues, 
referred to as inducible Treg (iTreg)67. The Th17 lineage was initially identified based on the 
discovery of IL-23 as a strong inducer of IL-17 producing cells. Th17 cells mainly secrete IL-
17A, IL-17F, IL-21 and IL-22. Th17 cells differentiate from naive CD4+ precursors in the 
presence of TGF-β and IL-6 or IL-21 driven by the master transcription factor RORγt68,69. 
T lymphocytes migrate into the CNS during health and disease12. Under steady-state 
conditions very few T cells were found to cross the BBB but could be detected within the 
brain parenchyma70. Very little is known about the phenotype those cells acquire after having 
penetrated the BBB and what cells are engaged in their re-activation. During pathological 
conditions such as infections, ischemia or inflammatory diseases (e.g. MS), leukocytes are 
found to traffic into the CNS parenchyma13. Under the same pathological conditions, 
microglia can up-regulate a distinct set of molecules needed for antigen presentation, like 
MHCII, CD40 or CD86. In vitro studies clearly showed antigen presenting capacities of 
microglia71,72, however, it is still debated whether microglia present myelin antigens to 
autoreactive T cells in vivo thereby potentially contributing to MS pathology. Indirect evidence 
is provided by experiments using mice depleted of microglia (CD11b-HSVTK) that showed 
repressed development of EAE disease49. Other studies demonstrated that their relative 
capacity in priming CD4+ T cells is lower than that of professional APC, such as DCs72–74. 
Microglia isolated ex vivo from the brain of EAE mice were shown to efficiently present 
exogenous and endogenous CNS antigens75. Because microglial cells are able to migrate to 
sites of CNS injury, up-regulate APC molecules and secrete pro-inflammatory as well as anti-
inflammatory cytokines, their contribution in regulating CD4+ T cell responses is quite 
possible. 
1.5 Regulatory T cells 
Ensuring immune homeostasis and maintaining immunological self-tolerance are the main 
tasks of CD4+ regulatory T cells (Treg). The term “regulatory” hereby refers to its ability to 
transfer immune unresponsiveness in vivo from one animal to another76. Disturbances in 
Treg function or numbers have been implicated in many autoimmune diseases, such as 
multiple sclerosis, rheumatoide arthritis, Crohn's disease or autoimmune liver disease. 
Regulatory T cells can be developmentally classified into natural, thymus-derived Treg 
(nTreg) and peripherally induced Treg (iTreg), both exhibiting suppressive activity in order to 
control pathological and physiological immune responses77. Different subsets of peripherally 
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induced Treg were identified, such as IL-10-secreting Tr1 cells78 or TGFβ-secreting Th3 
cells79, whose participation in the physiological control of adaptive immune responses and 
self-tolerance need to be further clarified. 
Most Treg cells constitutively express CD2577, the α chain of the IL-2 receptor, and therefore 
CD25 has been used for long to characterize Treg cells. However, CD25 expression is not 
exclusive for Treg cells, but also apparent on non-regulatory activated CD4+ T cells. In 
addition to CD25 further characterization revealed that the expression of other surface 
markers such as glucocorticoid-induced tumour necrosis factor receptor (GITR) or cytotoxic 
T-lymphocyte antigen-4 (CTLA-4) are also implicated in regulatory function80–82, but their 
expression is also seen in other activated CD4+ T cells. Finally, the Foxp3 transcription factor 
forkhead box P3 was identified as being the master regulator for development and function of 
regulatory T cells83,84. A defect in foxp3 gene expression was first found in the Scurfy 
mouse85, an x-linked recessive mutant strain, that is lethal in hemizygous males one month 
after birth and characterized by overproliferation of CD4+ T cells and overproduction of 
numerous, proinflammatory cytokines86. In humans, several mutations within the foxp3 gene 
had been linked to the X-linked syndrome of immune dysregulation, polyendocrinopathy, 
enteropathy (IPEX), characterized by an early onset of multiorgan autoimmunity87. The 
clinical and immunological similarities between IPEX patients and the Scurfy mouse lead 
researchers to suggest that foxp3 deficiency results primarily in the lack of functional 
regulatory T cells, rather than in the failure to repress inflammatory cytokine expression88. In 
line with that, further experiments demonstrated that retroviral transduction of foxp3 
converted naive CD4+ T cells into functionally suppressive T cells in mice89. To facilitate 
studies of Treg development and function, Foxp3EGFP reporter mice were generated90,91. With 
this approach, several groups also demonstrated a developmental relationship between 
Th17 and peripherally induced Treg lineages91,92. Upon antigen-specific activation, CD4+ T 
cells can transiently co-express Foxp3 and RORγt in the presence of TGF-β93 and 
differentiate depending on dominance of IL-6 or retinoic acid into Th17 or Foxp3+ regulatory 
T cells, respectively92. Together, Foxp3 resembles not only a Treg-specific marker, but also a 
lineage commitment factor for regulatory T cells in mice. However, there are differences 
between humans and mice particularly regarding the regulatory phenotype of Foxp3+ T cells. 
As with mice, natural occurring and peripherally induced human regulatory T cells both 
express the Foxp3 transcription factor. However, recent studies demonstrated that Foxp3 
expression can be induced in human CD4+ T cells by e.g. TCR-mediated activation without 
any suppressive activity of resulting Foxp3+ cells94,95. 
Several models exist by which regulatory T cells can mediate suppression and modulation of 
immune cells. One line of evidence suggests that suppression requires direct cell contact 
between Treg and effector T cells thereby inhibiting effector T cell proliferation96. Other 
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studies proved that immunosuppressive IL-10 secreted by Treg cells mediates tolerance97,98. 
Likewise, in a model of airway tolerance induced by a low dose of inhaled antigen, 
membrane-bound TGF-β on Foxp3+ Treg cells was shown to be important for their 
immunosuppressive ability in a cell contact-dependent way99. In another scenario, regulatory 
T cells act by, e.g. down-regulating CD40, CD80, and CD86 co-stimulatory molecules on 
DCs100, thereby interfering with T cell activation101. Most likely, CD4+CD25+Foxp3+ Treg 
suppressor mechanisms involve a combination of all, cytokine release, cell-cell contact and 
APC modulation. 
1.5.1 Induction of regulatory T cells in the periphery 
Upon identification of the fundamental role of regulatory T cells in immune homeostasis, 
allograft rejection, inhibition of autoimmune phenomena and allergic reactions82, much effort 
has gone into developing protocols to expand or induce alloreactive or antigen-specific Treg 
cells for therapy in vivo or in vitro. A few examples for induction of regulatory T cells from 
naive CD4+ precursors in the periphery are given below. 
The oral administration of low-dose antigen is the most prominent way of tolerance induction 
in vivo102. This so called mucosal tolerance is mediated by Th2, Th3 and Foxp3+ Treg cells 
and was applied to numerous autoimmune disease models, including EAE, uveitis and 
arthritis, plus non-autoimmune diseases such as asthma, atherosclerosis, graft rejection, 
allergy, colitis, stroke, and models of Alzheimer's disease79,102,103. In an early study, the oral 
administration of myelin basic protein (MBP) demonstrated EAE suppression in SJL mice 
mediated by peripheral tolerance induction. T cells isolated from these tolerized mice 
produced predominantly TGF-β, IL-10 and IL-4104. In turn, high doses of antigen together with 
a strong activation of DCs lead to increased T cell proliferation rather than conversion of 
Foxp3+ Treg cells in a subcutaneous immunization set up designed for studying the 
extrathymic of naive T cells105. In that study, the idea of “subimmunogenic” DC stimulation 
came up, which describes the combination of low-dose antigen and the lack of co-
stimulation. Antigen-unspecific induction of Foxp3+ Treg cells was observed, when glatiramer 
acetate (GA, Copaxone), a drug approved for MS therapy, was administered 
subcutaneously106. GA treatment induced anti-inflammatory type II monocytes characterized 
by increased IL-10 and TGF-β secretion, reduced co-stimulatory molecule expression and 
reduced STAT-1 phosphorylation upon stimulation. On top, when adoptively transferred GA-
treated type II monocytes reversed established EAE106. 
In addition to in vivo Treg conversion, much of the research is focused on generating 
antigen-specific or polyclonal Treg cells for adoptive immunotherapy in vitro. Methods used 
for antigen-specific expansion include the repetitive stimulation of Treg exhibiting antigen 
specificity against an allopeptide with suboptimal peptide-primed DCs107. Repetitive 
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stimulation with anti-CD3/CD28 coated Xcyte beads108 or anti-CD3/CD28 stimulation in the 
presence of artificial APC (CD32+ L cells)109 was reported for polyclonal Treg expansion. 
Using Xcyte beads, the authors report on 200-fold expansion of human Treg, whereas 
artificial APC led to an average 13.000-fold expansion within 3-4 weeks, while maintaining 
suppressive activity. All approaches require high doses of exogenous IL-2 to induce 
proliferation. 
1.5.2 Regulatory T cells in the CNS 
Although many studies examined the role of regulatory T cells in autoimmune and also 
neurodegenerative disease settings, such as EAE or stroke110–112, only a few addressed the 
presence of Treg cells directly in the CNS. First evidence came from studies with IL-10 
deficient mice, which developed a more severe EAE compared to wild-type mice110–112. This 
was supported by finding high levels of IL-10 in the CNS during recovery phase in a model of 
relapsing-remitting EAE86. Moreover, the adoptive transfer of regulatory T cells, as IL-10 
producers and suppressors of autoimmune responses, conferred protection from EAE114. In 
addition, the accumulation of Foxp3-expressing regulatory T cells directly in the CNS was 
shown to correlate with EAE recovery phase, whereas depletion of CD25+ cells inhibited 
recovery82. In turn, more recent data suggested that natural autoantigen-specific Treg cells 
accumulate in the CNS but fail to control ongoing autoimmune inflammation110 in chronic 
progressive EAE. This highlights how little is known about the exact mechanisms by which 
regulatory T cells contribute to attenuating EAE pathology and the question remains, whether 
regulatory T cells prevent trafficking of autoreactive Th1 cells into the CNS or are themselves 
targeted to the CNS111. 
Another line of evidence came from studies in brain ischemia. One report suggested a role 
for IL-10 secreting regulatory T cells in the functional outcome after acute experimental 
stroke (MCAO)111. Besides demonstrating increased infarct size, pro-inflammatory cytokine 
expression and enhanced microglia activation after depletion of Treg cells, this report proved 
that Foxp3+ Treg cells start infiltrating into the ipsilateral hemisphere 3 days after MCAO112. 
Another group used animals tolerized to myelin-antigens before experimental stroke to show 
that TGF-β-secreting T cells in the brain mediate neuroprotection112. In summary, the 
presence of regulatory T cells in the CNS and their contribution to local immune responses in 
CNS autoimmune disease or secondary inflammation after stroke or brain injury is not fully 
understood. 
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1.6 Aim of the Study 
Previously, our lab reported on how brain infiltrating effector T cells affect microglial 
expression of co-stimulatory molecules depending on their polarization (Th1 versus Th2)118. 
In a next study, our group demonstrated reduced EAE severity in mice subjected to 
entorhinal cortex lesion, suggesting a long-term tolerogenic effect induced by fiber tract 
injury119. To further clarify the mechanism of long-term tolerance towards brain antigens we 
examined the role of regulatory T cells. The central question of this thesis was whether and 
to what extend microglia cells can directly induce a regulatory T cell response. 
 
We hypothesized that microglia activation is a fine-tuned mechanism contributing to immune 
regulation in the CNS. In this thesis the CD4+ T cell interactions with microglia were studied 
regarding 
 
 (I) CD4+ T cell activation/differentiation during co-culture, 
 
 (II) characterization of microglial phenotypes and 
 
 (III) potential in vivo implications of MHCII expression within the CNS. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Mice 
C57Bl6/J wild-type mice were purchased from Elevage Janvier (Le Genest St. Isle, France). 
Foxp3EGFP reporter mice (on C57Bl6/J background) were provided by B. Malissen (CIML, 
France) and have been described previously90. T cell receptor transgenic C57BL/6-
Tg(Tcra2D2, Tcrb2D2)1Kuch/J mice, commonly known as 2D2 mice, C57Bl6/J-Thy1.1 
congenic mice and Major Histocompatibility Complex Class II (MHCII) deficient mice 
(B6.129S2-H2dlAb1-Ea/J) were purchased from The Jackson Laboratory (Maine, USA). The 
2D2 mice, reactive to myelin oligodendrocyte glycoprotein (MOG35–55), were intercrossed with 
Foxp3EGFP reporter mice to obtain 2D2.Foxp3EGFP mice (Fig. 2.1). IL-10 deficient (IL-10-/-) 
mice on C57Bl6/J background were provided by A. Hamann (DRFZ, Germany). All mice 
were bred and maintained under specific pathogen-free conditions at the animal facility of 
Charité - Universitätsmedizin Berlin. 
 
 
Fig. 2.1 Vβ11 profile of CD4+ T cells from 2D2.Foxp3EGFP transgenic mice. 
Blood samples of 6 weeks old mice were analyzed for the expression of MOG-specific TCR (Vβ11) and 
Foxp3EGFP by flow cytometry. 
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2.1.2 Kits 
Kit System Manufacturer 
Anti-Mouse/Rat Foxp3 Staining Set PE eBioscience 
BD Cytofix/Cytoperm BD 
DNeasy Blood Kit  QIAGEN 
FlowCytomix™ Basic Kit eBioscience 
Mouse CD4+CD25+ Regulatory T Cell 
Isolation Kit 
Miltenyi Biotec 
Mouse CD4+ T Cell Isolation Kit II Miltenyi Biotec 
Mouse CD90.2 MicroBeads Miltenyi Biotec 
Mouse IL-10 Platinum ELISA eBioscience 
Mouse IL-10/ TNFα /IL-4 / IL-23/ MCP-1/ IL-
17/ IL-6/ IL-13/ IFNγ FlowCytomix Simplex 
Kit 
eBioscience 
Mouse IL-17 Secretion Assay – Detection Kit Miltenyi Biotec 
Mouse IFNγ Secretion Assay – Detection Kit Miltenyi Biotec 
QuantiTect Rev. Transcription Kit QIAGEN 
RNeasy Mini Kit QIAGEN 
TaqMan® Fast Universal PCR Master Mix Applied Biosystems 
Table 2.1 Kits. 
All Kits were applied according to the manufacturer's instructions. 
2.1.3 Buffers and media 
Name Content 
DMEM 10% FCS, 1% Pen/Strep, 50 µM β-Me 
FACS buffer 2% FCS and 2 mM EDTA in PBS 
HBSS w/o and w Ca2+ and Mg2+ 
L929 supernatant media obtained by culturing confluent L929 
mouse fibroblasts for 14 days 
Red blood cell lysis buffer 9:1 mixture of 0.16 M NH4Cl, pH. 7.2, and 
0.17 M Tris base, pH 7.2 
RPMI-1640 10% FCS, 1% Pen/Strep, 50 µM β-Me 
Table 2.2 Buffers and media. 
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2.1.4 List of monoclonal antibodies 
Antigen Clone Manufacturer 
CD3ε 145-2C11 BD 
CD4 RM4-5 BD 
CD8 53-6.7 BD 
CD11b M1/70 BD 
CD11c N418 eBioscience 
CD25 PC61 BD 
CD28 37.51 BD 
CD45 30-F11 BD 
CD45R/B220 RA3-6B2 BD 
CD154 MR1 BD 
Foxp3 FJK-16s eBioscience 
IFNγ AN18.17.24 Miltenyi 
IL-4 11B11 BD 
IL-17 TC11-18H10 Miltenyi 
IL-17a MM17F3 eBioscience 
MHC II M5/114.15.2 BD 
TCR β chain H57-597 BD 
Vα3.2 RR3-16 BD 
Vβ11 RR3-15 BD 
Table 2.3 List of monoclonal antibodies. 
2.1.5 List of pre-developed gene expression assays 
Assay ID Gene symbol Gene name 
Mm00439614_m1 IL-10 interleukin 10 
Mm00441724_m1 TGF-β transforming growth factor, beta 1 
Mm00441891_m1 CD40 CD40 antigen 
Mm00444543_m1 CD86 CD86 antigen 
Mm00445235_m1 Cxcl10 chemokine (C-X-C motif) ligand 10 
Mm00482914_m1 CIITA class II transactivator 
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Assay ID Gene symbol Gene name 
Mm00492586_m1 IDO indoleamine 2,3 dioxygenase 1 
Mm00711662_m1 CD80 CD80 antigen 
Mm01261022_m1 Rorc RAR-related orphan receptor gamma 
Mm01309902_m1 iNOS nitric oxide synthase 2, inducible 
Mm01545399_m1 HPRT hypoxanthine guanine 
phosphoribosyl transferase 
Table 2.4 List of pre-developed gene expression assays. 
2.1.6 List of cytokines 
Cytokine Manufacturer 
GMCSF R&D Systems 
IFNγ Peprotech 
IL-2 R&D Systems 
IL-10 R&D Systems 
IL-12 R&D Systems 
MCSF Peprotech 
Table 2.5 List of cytokines. 
2.1.7 List of reagents 
Reagent Manufacturer 
Baytril Bayer 
Brefeldin A Sigma-Aldrich 
Cell proliferation dye eFluor® 670 eBioscience 
Clodronate Calbiochem 
Collagenase VIII Sigma 
DNase I Roche 
DMEM Gibco 
EDTA Invitrogen 
FCS (s 0115/Ch:1073 S) Biochrome 
Freunds Complete Adjuvant Difco Laboratories/ BD 
Glucose B. Braun 
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Reagent Manufacturer 
HBSS w/o and w Ca2+, Mg2+ Gibco 
Histopaque 1083 Sigma 
Ionomycin Cell Signaling Technology 
Ketamine Sigma-Aldrich 
MBP Biosynthan 
MOG Pepceuticals 
Mycobacterium tuberculosis H37 Ra Difco Laboratories/ BD 
Penicillin/Streptomycin Invitrogen 
Percoll Biochrome AG 
Pertussis toxin List Biological Laboratories 
Rompun Bayer 
Poly-D-Lysine Millipore 
RPMI-1640 Gibco 
SNARF-1 Molecular Probes 
Trypsin-EDTA Gibco 
2-Mercaptoethanol Gibco 
Table 2.6 List of reagents. 
2.1.8 List of consumable material 
Consumables Manufacturer 
Cell strainer, 40 µm and 70 µm BD 
Cell culture flasks 75 cm2 BD 
Cell Separation Columns MS, LS, LD Miltenyi Biotec 
Combitips 10 ml Eppendorf 
Conical Centrifuge Tubes 15 ml, 50 ml BD 
Filter Tips 2.5 - 1000 µl Sarstedt 
Microplates and multi-well plates BD 
MiniCollect EDTA Tubes 0.5 ml Greiner Bio-One 
Needles B. Braun Melsungen AG 
PCR SoftTubes 0.2 ml Biozym Diagnostik GmbH 
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Consumables Manufacturer 
Pipettes 2.5 – 25 ml BD 
Round bottom test tubes BD 
Safe Lock Tubes 0.5 - 2 ml Eppendorf 
Syringes  BD 
3-Way Stopcock B. Braun Melsungen AG 
Table 2.7 List of consumable material. 
2.1.9 List of Instrumentation 
Instruments Manufacturer 
Axiovert 135 Zeiss 
Centrifuge 5810 Eppendorf 
ELISA Reader/ Washer Tecan 
FACSAria BD 
FACSCanto II BD 
Incubator Binder 
LSR II BD 
Microcentrifuge 5415R Eppendorf 
7500 Real Time PCR System Applied Biosystems 
Table 2.8 List of general equipment. 
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2.2 Animal models 
2.2.1 Entorhinal cortex lesion (ECL) and isolation of CNS infiltrating immune cells 
ECL involves the stereotactical lesion of the perforant path (Fig. 2.2), a myelinated fiber tract 
connecting the entorhinal cortex with the hippocampus, leading to anterograde degeneration 
of the hippocampus54. 
 
Fig. 2.2 Entorhinal cortex lesion (ECL) model. 
EC= Entorhinal Cortex, DG= Dendate Gyrus, PP= Perforant Path, CA1-3= Cornu Ammonis (adapted from Ch. 
Brandt) 
Stereotaxic surgery (ECL) was performed as previously described120. In brief, mice were 
anesthetized using a ketamin cocktail (20% Ketamin and 8% Rompun® in 0.9% NaCl; 
0.01 ml/g body weight). After exposing the skull, a burr-hole was drilled and the left 
entorhinal cortex was lesioned with a 2 mm scalpel adjusted to the following coordinates 
from Lambda: anterior-posterior 0.3 mm, lateral 1.8 mm and vertical down to the base of the 
skull. For sham operation, animals were anesthetized and the scalp incised. However, 
instead of opening the skull, the scalp was sutured back and animals were allowed to 
recover. For flow cytometric analysis 14 days later, blood samples were drawn from ECL 
operated animals before they were transcardially perfused with saline, and both 
hemispheres, lymph nodes and spleens were collected. From blood samples, lymphocytes 
were separated using Histopaque 1083 (Sigma). Single cell suspensions from lymph nodes 
and spleen were prepared by forcing the tissues through a cell strainer (pore size 70 µm). 
For flow cytometric analysis of brain infiltrating cells, 1/3 of lesioned posterior ipsi- or 
contralateral hemisphere was incubated for 30 min at 37 °C with Collagenase VIII (Sigma) for 
dissociation. The tissue was squeezed through a 70 µm cell strainer and mononuclear cells 
were separated using Percoll (Biochrome AG) gradient centrifugation (30 min) with a 
gradient of 35% and 70%. Cell suspensions from brain, lymph nodes, spleen and blood were 
stained for FACS analysis (FACSCanto II, BD). 
2.2.2 Mixed bone marrow chimeras 
Mixed bone marrow chimeras were generated as previously described121. Bone marrow from 
the femurs of male C57Bl6/J wild-type (WT) and MHCII deficient (MHCII-/-) and Foxp3EGFP 
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mice was isolated and depleted of CD90.2+ cells using anti-CD90.2 beads (Miltenyi Biotec). 
WT, MHCII-/- or Foxp3EGFP bone marrow (8 x 106 cells) was administered intravenously into 
respective recipient mice after lethal irradiation (1100 cGy) given as a split dose. Mice were 
kept on antibiotics (0.001% Baytril® (Bayer) in drinking water) for 6-8 weeks after 
reconstitution until they were subjected to blood phenotyping. On the day before sterotaxic 
surgery (ECL) all chimeric mice received 2 x 107 purified CD4+ T cells (CD4 T cell isolation 
kit, Miltenyi Biotec) from Foxp3EGFP reporter mice. 
2.2.3 Experimental autoimmune encephalomyelitis (EAE) 
Female C57Bl6/J mice were immunized s.c. at four sites on the flank with 250 µg of MOG35-55 
peptide (MEVGWYRSPFSRVVHLYRNGGK, Pepceuticals, UK) emulsified in complete 
Freund’s adjuvant containing H37 RA (BD Bioscience). On the day of immunization and two 
days later, pertussis toxin (400 ng, List Biological Labs, CA) was administered i.p. Mice were 
observed for clinical signs of EAE (paralysis progressing from tail to head) for up to 30 days 
and scored daily using the following scale: (0) no disease, (1) limp tail and/or hind limb 
ataxia, (2) hind limb paresis, (3) hind limb paralysis, (4) hind limb and fore limb paralysis, and 
(5) death. 
2.3 Cell biology protocols 
2.3.1 Generation of Th1 cells 
We generated Th1 cells as previously described122. CD4+ T cells were isolated from lymph 
nodes and spleens of C57Bl6/J mice using CD4+ T Cell Isolation Kit II (Miltenyi Biotec). Cells 
were seeded at a density of 1 x 106/ml in complete RPMI-1640 and stimulated with a cocktail 
of 5 µg/ml anti-CD3ε, 5 µg/ml anti-CD28, 1 µg/ml anti-IL-4 and 1 ng/ml IL-12. Two days later 
IL-2 was added to final concentration of 1 ng/ml. Cells and cell supernatant were harvested 
on day 4-5 after preparation. 
2.3.2 Generation of bone marrow derived macrophages and dendritic cells 
Bone marrow was isolated from the femur, tibia and humerus of adult C57Bl6/J mice by 
cutting off bone ends and flushing it out using a syringe. The cell suspension was filtered 
(70 µm cell strainer) to remove any bone and tissue fragments and centrifuged for 5 min at 
1200 rpm. Erythrocytes were lysed in Tris-NH4Cl solution. Bone marrow cells were seeded at 
a density of 7.5 x 105/ml in complete RPMI-1640 and stimulated with 2 ng/ml MCSF 
(Peprotech) to be differentiated into macrophages and 10 ng/ml GMCSF (Peprotech) for 
bone marrow derived dendritic cells. After 6 days of culture, adherent cells were harvested 
and analyzed by flow cytometry (FACSCanto II, BD) for CD11b, CD11c and MHCII. 
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2.3.3 Generation of primary microglia 
Mixed glial cell cultures were prepared from cerebral cortex of newborn (P0-2) mice as 
described previously123. In brief, cortices and brain were obtained and the bloodvessels and 
meninges were carefully removed. Tissues were dissected and subjected to enzymatic 
dissociation (25 µg/ml DNase I (Roche) in 0.05% Trypsin-EDTA (Invitrogen), 10 min at 
37°C), washed in FCS containing HBSS and resuspended in complete DMEM. Mixed glial 
cells were cultured in poly-D-lysine-coated (Sigma) flasks at 37°C and 5% CO2. The day 
after preparation, cell debris was removed and the media replaced. After 10-12 days, 
microglia were separated from the underlying astrocytic layer by gentle shaking of the flask. 
Cultures usually contained > 95% microglial (CD11b+) cells, as determined by flow cytometry 
(FACSCanto II, BD). 
2.3.4 Generation of adult microglia 
Mixed glial cell cultures were prepared as described above. On the second day after 
preparation, mixed glial cultures were stimulated with L929 cell conditioned media. Another 
two days later, the bisphosphonate clodronate (200 µg/ml for 48 h, Calbiochem) was used 
to selectively deplete postnatal microglia. Dead cells were removed by gentle agitation of the 
flask over night. Adult microglia were isolated from cortices, cerebellum and brainstem of 
male C57Bl6/J mice. The tissue was homogenized and incubated with 2.5% Trypsin 
(Invitrogen) at 37°C for 10 min. FCS containing media was used to stop enzymatic digestion 
and cells were pelleted (130 x g, 10 min). DNase I was added to remove DNA and the cell 
suspension was forced through a 40 µm cell strainer before seeding the adult brain cells onto 
the postnatal astrocytic layer. After one week of culture in the presence of L929-conditioned 
media, adult microglial cells were harvested by gentle shaking of the flask. 
2.3.5 Microglia – T cell co-culture 
Microglia were seeded into 96-well plates (4 x 105/ml) in complete DMEM and stimulated 
24 h later with recombinant IFNγ (Peprotech) at final concentrations of 10 U/ml for low-dose 
and 100 U/ml for high-dose condition, respectively. Another 24 h later, cells were pulsed with 
myelin oligodendrocyte glycoprotein (MOG35-55) peptide (MEVGWYRSPFSRVVHLYRNGGK, 
Pepceuticals) at final concentrations of 1 µg/ml for low-dose and 10 µg/ml for high-dose 
stimulation, respectively. Untouched CD4+ T cells were purified from lymph nodes and 
spleens of 2D2.Foxp3EGFP mice on C57Bl6/J background using CD4+ T cell isolation Kit II 
(Miltenyi Biotech), if not indicated otherwise. Stimulated microglia cultures were washed, 
isolated CD4+ T cells were seeded onto the microglial layer (2 x 106/ml) and co-cultured for 7 
days (37°C, 5% CO2). Following co-culture, CD4+ T cells were harvested, stained for CD11b, 
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CD4 and CD25, and analyzed by flow cytometry (FACSCanto II, BD) for the expression of 
GFP (Foxp3) and respective cell markers. 
 
For Kinetic analysis of microglia-mediated T cell response, CD4+ T cells were harvested and 
analyzed on a daily base for indicated markers. In addition, supernatants were collected and 
analyzed for cytokine secretion pattern using FlowCytomix Multiple Analyte Detection 
System (eBioscience). 
 
For microglia-mediated de novo generation of Foxp3+ Tregs, CD4+ T cells were further 
depleted for CD25 and Foxp3EGFP positive cells by flow cytometry (FACSAria, BD) (purity 
> 99%). CD4+CD25-Foxp3- cells were then seeded onto the microglial layer and co-cultured 
for 7 days. 
 
For analyzing proliferation of microglia-induced Treg cells, purified CD4+ T cells were 
incubated in PBS containing 5 µM cell proliferation dye eFluor® 670 (eBioscience) for 10 min 
at 37°C before co-culturing them with activated microglia. Proliferation was assessed on day 
2 (control) and day 6 of co-culture by analyzing dilution of eFluor® 670 using flow cytometry 
(FACSCanto II, BD). 
 
For analyzing MHCII dependency in microglia-mediated Tregs induction, postnatal microglia 
were prepared from MHCII deficient mice (B6.129S2-H2dlAb1-Ea/J) and used for the co-culture 
assay. 
 
For analyzing functional activity of microglia-induced Treg in vivo, CD4+CD25+ T cells were 
purified from co-cultures after 7 days using CD4+CD25+ Regulatory T Cell Isolation Kit 
(Miltenyi Biotech) and adoptively transferred into female C57Bl6/J recipients one day before 
they were subjected to immunization of EAE. 
2.3.6 T cell suppression assay 
SNARF-1 labeled CD4+ responder T cells (3 x 105/well) from 2D2 mice were seeded together 
with irradiated splenic cells (5 x 105/well) in a 96-well plate. FACS-sorted (FACSAria, BD) 
microglia-induced CD4+CD25+Foxp3+ Treg cells and responder T cells were co-cultured at 
various ratios ranging from 1:5 up to 1:100 in the presence of TCR peptide (10 µg/ml  
MOG35-55) for 4 days (37°C, 5% CO2). Proliferation of responder T cells was assessed by 
SNARF-1 dilution (emission at 640 nm) using flow cytometry (FACSCanto II, BD). Foxp3EGFP+ 
T cells were excluded prior to analysis. In control experiments, SNARF-1 labeled responder 
T cells were co-cultured with FACS-sorted microglia-induced effector T cells 
(CD4+CD25+Foxp3-). 
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2.3.7 Intracellular cytokine staining 
Microglia-induced T cells were harvested from high-dose activated co-cultures and incubated 
in RPMI-1640 (1 x 107 cells/ml) containing 5 µg/ml CD28 (BD), 20 ng/ml PMA (Sigma) and 
1 µg/ml ionomycin (Sigma) for 2 h (37°C, 5% CO2). Brefeldin A (Sigma) was added to final 
concentration of 1 µg/ml and cell suspensions were incubated for another 2 h. Following that, 
cells were stained for the surface markers CD4 and CD25 before fixation and 
permeabilization using Cytofix/Cytoperm (BD). Finally, cells were intracellularly stained for 
IFNγ and IL-17 (Miltenyi Biotec) and analyzed (LSR II, BD). 
2.3.8 Blood lymphocyte phenotyping 
Blood samples were obtained from the facial vein of mice and transferred into 500 µl EDTA 
solution (2 mM) and layered onto 500 µl Histopaque 1083 (Sigma). Following 20 min 
centrifugation (200 x g) the phases were separated with a tight ring of PBMCs in between. 
The lymphocyte fraction was collected, washed and stained for further flow cytometric 
analysis. 
2.4 Molecular biology protocols 
2.4.1 Methylation studies 
Microglia-induced Treg cells from low-dose co-cultures and sexmatched nTreg cells from the 
lymph nodes of C57Bl6/J were purified using CD4+CD25+ Regulatory T Cell Isolation Kit 
(Miltenyi Biotech). Genomic DNA was isolated using DNeasy Blood Kit (Qiagen) according to 
the manufacturer’s protocol. DNA samples were analyzed for the degree of methylation of 
individual CpG motifs within the murine foxp3 locus as previously described124. Two 
overlapping amplicons were analyzed by bisulfite sequencing (Epiontis GmbH, Berlin). 
Notably, Treg cells purified from co-cultures and lymph nodes were enriched for CD25, not 
Foxp3, resulting in a CD4+Foxp3+ : CD4+Foxp3- ratio of 1:1 (Treg : Teff). 
2.4.2 Real-Time PCR (qPCR) 
For extraction of total RNA from microglia the cell-lysat was homogenized by QIAshredder 
spin columns (Qiagen) and RNA was further purified using RNeasy mini spin columns 
(Qiagen). For cDNA synthesis the QuantiTect reverse transcription kit (Qiagen) was applied. 
Subsequently, pre-developed TaqMan gene expression assays and TaqMan Fast Mastermix 
(Applied Biosystems) were used for amplification of mRNA transcripts. Hprt served as 
housekeeping gene. The results for the relative gene expression were calculated using  
2-ΔΔCT-method. All amplification reactions were performed on ABI PRISM 7500 Fast Real 
Time PCR System (Applied Biosystems). 
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3 Results 
3.1 Results (I) – CD4+ T cell activation/differentiation during co-culture 
This part is focused on the T cell response of microglia – T cell co-culture and describes the 
induction and kinetic of Foxp3+ regulatory T cells, co-culture cytokine pattern, microglia-
mediated T cell proliferation and de novo induction of Foxp3+ Treg and their suppressive 
function in vitro and in vivo. 
3.1.1 Microglia induce CD4+Foxp3+ regulatory T cells 
To study whether the neuroimmune system has the potential to achieve an alternative 
activation state similar to that of peripheral macrophages/ type II monocytes, we investigated 
antigen-presenting properties of microglia and their phenotypic and functional changes 
leading to beneficial (regulatory T cell) or detrimental (effector) T cell responses in vitro. 
Since IFNγ is known to promote cell surface expression of MHC class II molecules on 
microglia125, we set up an in vitro co-culturing system mimicking different microglial activation 
states by using recombinant IFNγ in combination with the neuronal antigen myelin 
oligodendrocyte glycoprotein (MOG). We stimulated microglial cells with either low-dose 
(10 U/ml /1 µg/ml) or high-dose (100 U/ml /10 µg/ml) IFNγ/MOG, to characterize the effect of 
microglial activation/maturation stages on the CD4+ T cell response. CD4+ T cells were 
isolated from 2D2 mice intercrossed with Foxp3EGFP reporter mice (2D2.Foxp3EGFP), providing 
us with MOG-specific CD4+ cells which express green fluorescent protein (GFP) in Foxp3 
positive Treg cells. 
Interestingly, upon interaction with low-dose primed microglia, naive CD4+ T cells 
preferentially differentiated into CD25+Foxp3+ regulatory T cells (33 ± 1.9%, Fig. 3.1 a, b). In 
contrast, high-dose activated microglia induced the expansion of CD25+Foxp3- T effector 
cells (33.7%, Fig. 3.1 a) rather than CD25+Foxp3+ Treg cells (9.5 ± 1.4%, Fig. 3.1 b). The 
plain co-culture with unstimulated microglia (control) did not evoke a Treg or effector T cell 
response (Fig. 3.1 a, b) and resulted in a substantial loss in the number of CD4+ cells. In the 
same way, pulsing microglia with MOG peptide alone was not sufficient to induce a 
regulatory or effector CD4+ T cell response (Fig. 3.1 a, b). Stimulating microglia with low-
dose IFNγ alone partially induced an effector T cell response, but did not result in 
differentiation of Treg cells (Fig. 3.1 a, b). This clearly demonstrates that microglia can 
directly influence antigen specific CD4+ T cell responses depending on IFNγ and antigen 
levels confronted with. 
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Fig. 3.1 Microglia induce Foxp3+ Treg cells preferentially under low-dose conditions. 
Microglia were differentially stimulated and co-cultured with MOG-specific CD4+ T cells from 2D2.Foxp3EGFP 
mice. Red arrow indicates day of analysis. (a) T cells were analyzed by flow cytometry for the expression of 
Foxp3 and CD25. Density plots are gated for live T cells, CD11b- and CD4+. Numbers in rectangle gates indicate 
percent of Foxp3+ cells. Data are representative for n = 4-7 separate experiments, summarized in (b) (mean ± 
SEM, Student’s t test). 
 
Fig. 3.2 CD4+ T cells are selectively aggregated around activated microglia. 
Pictures were taken 48 h after beginning of co-culture using 20 x objective on Axiovert 135 (Zeiss, Germany) 
microscope and AxioVision Rel. 4.7 (Zeiss, Germany) software. Black arrows indicate T cell-microglia 
aggregates. 
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To test, whether the observed T cell response requires physical interaction of T cells and 
microglia, we monitored the T cell behaviour on microglial cultures. CD4+ T cells formed 
aggregates around microglia starting 48 h after the beginning of co-culture, but only when 
microglia had been activated by IFNγ/MOG (Fig. 3.2). These findings suggest, that the 
mechanism of microglia-mediated Treg and effector T cell induction is cell contact-
dependent. 
3.1.2 Dynamics of microglia-mediated Treg and Teff induction 
Kinetic analysis of Foxp3/CD25 expression revealed the first evidence of induction of Foxp3+ 
cells in low-dose primed co-cultures not earlier than on day 3 (Fig. 3.3 a, b), which is 24 h 
after we observed CD4+ T cells forming aggregates around microglia (Fig. 3.2). 
  
 
Fig. 3.3 Dynamics of microglia-mediated Treg and Teff induction. 
(a) The emergence of CD4+CD25+Foxp3- Teffs and CD4+CD25+Foxp3+ Treg cells was analyzed on 7 
consecutive days (red arrows) by flow cytometry comparing co-cultures of low- and high-dose activated 
microglia. Numbers in upper quadrants indicate percent of CD25+Foxp3- and CD25+Foxp3+ cells. Dot plots are 
representative of n = 3 separate experiments, summarized in (b) for GFP+(Foxp3) Tregs (mean ± SEM). 
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Notably, even before Foxp3+ Treg cell induction, there is a raising population of CD25+Foxp3- 
effector T cells also under low-dose condition (Fig. 3.3 a). The percentage of Foxp3 
expressing Treg cells constantly increased in low-dose co-cultures over 7 days (Fig. 3.3 b). 
Foxp3 expression was further restricted to the population of CD25 expressing cells (Fig. 
3.3 a). In contrast, high-dose stimulated microglia induced a pool of CD25+Foxp3- effector 
cells starting from the first day of co-culture (40.9%) up to 89.6% on day 4 (Fig. 3.3 a). These 
two distinct trends of CD4+ T cell response observed after varying IFNγ and MOG 
concentrations by a factor of 10 suggest a fine-tuned mechanism by which microglia react to 
IFNγ levels. In addition, finding an activation state in which microglia predominantly induced 
regulatory T cells raised the question whether microglia induce proliferation or de novo 
generation of Foxp3+ Treg from naive precursors. 
3.1.3 Microglia-induced CD4+ T cell response reveals functional plasticity 
In order to classify microglia-mediated T cell responses in more detail we determined the 
cytokines that were produced in microglia-T cell co-cultures using bead-based multiplex 
immunoassay for flow cytometry (Fig. 3.4). Both IFNγ/MOG concentrations substantially 
increased levels of pro-inflammatory TNFα, with marginal higher TNFα production when 
stimulated with high-dose IFNγ/MOG and a certain background TNFα level when stimulation 
was incomplete (IFNγ only). A similar secretion pattern was observed for the chemokine 
MCP-1, certainly secreted by microglia (Fig. 3.4, MCP-1 panel). Over 4 times higher IL-6 
levels (630 pg/ml, Fig. 3.4, IL-6 panel, day 3) were detected in supernatants of high-dose 
treated microglial co-cultures versus supernatants from low-dose co-culture (140 pg/ml). In 
line with the enhanced IL-6 production, we found a massive increase of IL-17 levels 
(180 pg/ml, Fig. 3.4, IL-17 panel, day 2) in high-dose activated co-cultures, pointing towards 
a Th17 response. Interestingly, the same stimulation condition exclusively induced significant 
levels of IL-13 (1290 pg/ml, Fig. 3.4, IL-13 panel, day 3) and IFNγ (360 pg/ml, Fig. 3.4, IFNγ 
panel, day 1), cytokines known to be secreted during Th2 and Th1 immune responses. 
In turn, low-dose stimulation resulted in the highest production of anti-inflammatory IL-10 on 
day 1-4 of co-culture. Notably, we did not detect any IL-4, IL-1β or IL-23 in our experimental 
set-up. Regarding the kinetics of secreted cytokines TNFα levels showed only marginal 
variations over time, whereas MCP-1, IL-6, IL-10 and IL-13 levels increased until day 4 and 
pro-inflammatory IL-17 and IFNγ decreased from the start of co-culture. 
In complementary experiments we used intracellular cytokine staining to further characterize 
the cells that secrete IL-17 and IFNγ. Interestingly, we identified IFNγ and IL-17 producers to 
originate from both populations, Foxp3+ Treg and Foxp3- Teffs (Fig. 3.5) Notably, similar 
frequencies of IFNγ and IL-17 producers were found also in low-dose treated co-cultures 
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(data not shown), suggesting that high-dose stimulation enhanced the amount of IFNγ and 
IL-17 on a per cell basis. This cytokine secretion pattern reflects the functional plasticity of 
microglia induced CD4+ T cell response, leading to secretion of Th1/Th2/Th17 cytokines 
when stimulated with high-dose IFNγ/MOG or anti-inflammatory IL-10 secretion in response 
to low-dose stimulation. This data set also indicates that the micromilieu, created by 
microglial cytokine and chemokine secretion, sensitively responds to the level of IFNγ/MOG. 
 
 
Fig. 3.4 Cytokine secretion pattern of microglia mediated CD4+ T cell responses. 
Kinetic analysis of co-culture supernatants using bead-based multiplex immunoassay (eBioscience) for the 
cytokines TNFα, MCP-1, IL-6, IL-13, IL-17, IFNγ and IL-10. Shown are representative data of three individual 
experiments. 
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Fig. 3.5 Identification of IFNγ and IL-17 producing cells. 
Microglia-induced T cells were harvested, restimulated, fixed, permealized and intracellularly stained with anti- 
IFNγ-PE and anti-IL-17-APC. Left) Histogram shows T cells derived from high-dose activated co-cultures gated 
for surface CD11b- and CD4+. Numbers above bracketed lines indicate percent of Foxp3- and Foxp3+ population, 
respectively. Right) Dot plots are showing intracellular cytokine staining for respective Foxp3+/- population. 
Data are representative of two separate experiments. 
3.1.4 Microglia-induced Treg: proliferation versus de novo generation 
To test, whether the accumulation of Foxp3+ Treg cells during co-culture with activated 
microglia results from proliferation of pre-existing Treg cells or from the conversion of naive 
precursors into de novo induced Foxp3+ Treg cells, we set up the following experiments. We 
used CD4+ T cells depleted of CD25+ and Foxp3+ cells (CD4+CD25-Foxp3- T cells, purity 
99%) for co-culture with activated and non-activated microglia. Co-culture with control 
microglia showed no induction of Foxp3+ cells (1.02%), whereas upon stimulation microglia 
induced de novo Foxp3+ regulatory T cells from naive CD4+ T cells. Under low-dose 
conditions 19.4% Foxp3+ Treg cells were induced, whereas high-dose stimulation of 
microglia resulted in only 10.4% de novo induced Foxp3+ Treg cells (Fig. 3.6). These 
findings indicate that activated microglia promote de novo induction of Foxp3+ regulatory T 
cells, preferentially when stimulated with low doses of IFNγ and MOG peptide. Notably, 
compared to total CD4+ cells (Fig. 3.1), de novo induced Foxp3+ Treg frequencies from low-
dose cultures were reduced. Therefore, we set up a second set of experiments to assess 
proliferation of Foxp3+ Treg cells. 
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Purified CD4+ T cells were labeled with the cell proliferation dye eFluor® 670 (eBioscience) 
before co-culture with microglia and analyzed for proliferation of Foxp3+ and Foxp3- cells 
after six days by flow cytometry. Fluorescent intensity of proliferation dye on day 2 was used 
as a baseline (Fig. 3.7). Co-culture experiments with labeled CD4+ T cells clearly showed 
proliferation of Foxp3+ Treg cells under both conditions, low-dose (17%) and high-dose 
(74%) stimulated microglia, whereas under control conditions T cells (Foxp3-/Foxp3+) did not 
divide (Fig. 3.7). Notably, under low-dose conditions Foxp3- cells showed less proliferation 
indicating a preferential induction of proliferation in Foxp3+ cells. In contrast, we found 70% 
of Foxp3- cells undergoing proliferation in high-dose stimulated microglia cultures. 
Thus, we conclude that the enhanced emergence of Foxp3+ Treg cells after co-culture with 
low-dose activated microglia can be explained as the sum of both, de novo induction of 
Foxp3+ Treg from naive CD4+ T cells as well as Treg proliferation in response to IFNγ/MOG 
induced tolerogenic signals. 
 
Fig. 3.6 De novo induction of Foxp3+ Treg cells after co-culture with microglia. 
Flow cytometric analysis of Foxp3+ expressing cells from co-culture of CD4+CD25-Foxp3- cells with control, 
low-dose and high-dose activated microglia. Red arrow indicates day of analysis. Numbers in upper right 
quadrants indicate percent of CD25+Foxp3+ cells. Data are representative of two individual experiments.  
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Fig. 3.7 Activated microglia induce cell proliferation in CD4+ T cells. 
CD4+ lymphocytes were labeled with 5 µM eFluor® 670 and co-cultured for 2 days (left panels) and 6 days 
(right panels) with activated and control microglia. For analysis cells were gated on CD11b- and CD4+. Data are 
representative of two separate experiments. Red arrows indicate day of analysis. 
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3.1.5 Microglia-induced Treg are epigenetically stable 
Recently, intrinsic Treg stability was shown to rely on epigenetic modification of the foxp3 
locus126. Because foxp3 demethylation is associated with stable Foxp3 protein expression, 
we analyzed two highly conserved CpG-rich Treg-specific demethylated regions (TSDR) 
from Treg cells induced by microglia and thymus derived CD4+CD25+ nTreg as control cells 
(Fig. 3.8). The extent of TSDR demethylation in microglia-induced Treg was comparable to 
that of thymus derived nTreg (Fig. 3.8), indicating a stable Foxp3 expression for microglia-
induced Treg cells. 
 
 
Fig. 3.8 Foxp3 methylation profile of microglia induced Tregs. 
CD4+CD25+ T cells were harvested 7 days after co-culture with low-dose activated microglia and the DNA-
methylation status of two overlapping amplicons within the mouse foxp3 locus was analyzed using bi-sulfide 
sequencing (Epiontis GmbH). Single CpG motifs are separated by horizontal lines resulting in boxes 
representing color-coded methylation rates (yellow = 0%, blue = 100% methylation). Upper panel illustrates 
microglia-induced Treg cells, lower panel depicts thymus-derived nTreg cells. 
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3.1.6 Microglia-induced Treg suppress the proliferation of encephalogenic T cells in vitro 
To investigate the suppressive capacity of microglia-induced Treg cells, we sorted 
CD4+CD25+Foxp3EGFP+ Treg from low-dose activated co-cultures for a MOG-driven 
suppression assay. Microglia-induced Treg cells efficiently suppressed the proliferation of 
SNARF-1 labeled responder T cells up to a ratio of 1:50 (Fig. 3.9 a upper panel, b). As 
control, we purified CD4+CD25+Foxp3EGFP- from the same cultures and observed no 
significant inhibitory effect on responder T cell proliferation (Fig. 3.9 a lower panel, b). These 
data indicate, that microglia-induced Treg are highly suppressive in vitro. 
 
 
Fig. 3.9 Microglia induce functionally suppressive Treg in vitro. 
Microglia induced Treg cells were harvested and sorted for Foxp3+ Treg and Foxp3- Teffs by flow cytometry. 
(a) shows the proliferation of SNARF-1 labeled responder T cells incubated with irradiated splenocytes and 
without MOG (no stimulation) or with irradiated splenocytes and MOG in the absence (stimulation) or presence 
of microglia induced Foxp3+ Treg (upper panel) and microglia induced Foxp3- Teffs (lower panel). The ratio of 
MOG-specific Treg/Teffs : responder T cells is indicated above plots. Numbers above bracketed lines refer to 
percent of proliferating cells. Data are representative for three separate experiments, summarized in (b), the 
proliferation index of both groups in percent of control (stimulation). 
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3.1.7 Microglia-induced Treg reduce EAE severity in vivo 
Recent studies suggested that the transfer of regulatory T cells isolated from peripheral 
lymph nodes protects against experimental autoimmune encephalomyelitis (EAE) induction 
and progression115. To examine the effect of microglia-induced Treg cells (miTreg) on the 
clinical disease course of EAE, we purified MOG-specific CD25+ miTreg and natural Treg 
(nTreg) from lymph nodes of naive WT animals and adoptively transferred them into 
C57Bl6/J mice. Control mice received PBS instead. The recipients were immunized with 
 
Fig. 3.10 Microglia-induced Treg are functional active in vivo. 
Microglia-induced Treg (miTreg) or thymus-derived Treg (nTreg) were adoptively transferred in sexmatched 
C57Bl6/J recipients (5 x 105 cells/mouse). EAE was induced by immunization with MOG35-55 peptide in 
complete Freund´s adjuvant (CFA). The course of EAE disease is shown in (a) as mean clinical score (+ SEM) 
for PBS treated mice (n = 19 open circles), microglia-induced Treg (miTreg) treated mice (n = 8, filled squares) 
and natural Treg (nTreg) treated mice (n = 10, filled circles) (*p<0.05, **p<0.01, Mann Whitney test comparing 
miTreg with nTreg). EAE describing statistics are summarized for incidence and mortality (b), mean days of 
onset post induction (p.i.) (c), mean days of disease peak post induction (p.i.) (d) and mean max. clinical score 
(e) (mean ± SEM, Student’s t test). 
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MOG35-55 in CFA one day after adoptive cell transfer. After immunization of mice, transfer of 
microglia-induced Treg cells resulted in a constantly reduced clinical disease severity, 
whereas the transfer of nTreg cells showed no explicit change in clinical scores compared to 
PBS treated recipients (Fig. 3.10 a). In addition, in the group receiving miTreg all mice 
survived, whereas PBS controls and mice receiving nTreg showed mortality rates of 37% 
and up to 50%, respectively (Fig. 3.10 b). A similar disease onset (between day 12-14) was 
observed within all groups (Fig. 3.10 c). Notably, animals developed classical EAE with 
100% incidence (Fig. 3.10 b). Together, these results prove that microglia-induced Treg cells 
are functionally suppressive in vivo. 
3.2 Results (II) – Characterization of microglial phenotypes 
This part is focused on the different microglia phenotypes acquired during activation and 
illustrates the importance of MHCII and co-stimulatory molecules and the role of IL-10 in 
modulating microglia phenotype. Furthermore microglia antigen presenting properties are 
compared to that of professional APCs and alternative ways in microglia activation are 
studied. 
3.2.1 Microglial induction of Treg is strictly MHCII dependent and antigen-specific 
To investigate how microglial MHC class II is affected by different doses of IFNγ and antigen, 
we analyzed microglia cultures 48 h after treatment for MHCII mRNA and molecule 
 
Fig. 3.11 IFNγ induces dose-dependent MHCII up-regulation. 
Microglia were analyzed 48 h after IFNγ/MOG stimulation for the expression of MHCII molecules using flow 
cytometry (a). Numbers above blue gates indicate percent of MHCII+ cells. Data are summarized in (b) as 
percent of MHCII+ microglia gated on CD11b+ cells (n = 4, mean ± SEM, Student’s t test). (c) x-fold increase of 
MHCII mRNA (n = 3, mean ± SEM, Student’s t test). Expression levels were normalized to the housekeeping 
gene Hprt. 
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expression. Dose-dependently, IFNγ/MOG induced a marked increase in MHCII molecule 
expression on microglia (Fig. 3.11 a). While low-dose treated cultures showed 24.38 ± 
1.08% MHCII+ microglia, high-dose treated cultures reached levels of 37.8 ± 1.92% MHCII+ 
microglial cells (Fig. 3.11 b). These data were confirmed by mRNA analyses, showing 
significant differences in MHCII up-regulation between low-dose (mean 256.7-fold ± 49.35) 
and high-dose (906-fold ± 89.11) compared to control (Fig. 3.11 c). 
 
To confirm that microglial induction of Foxp3+ regulatory Treg cells depends on antigen 
presentation in the context of MHC class II, we used primary microglia derived from MHCII 
deficient mice (MHCII-/-) for in vitro co-culture assays. Fig. 3.12 a illustrates that in contrast to 
WT microglia MHCII-/- microglia did not respond to IFNγ stimulation by upregulating MHC 
 
Fig. 3.12 Microglial induction of Foxp3+ Treg clearly depends on MHCII expression. 
(a) WT and MHCII-/- microglia were pulsed with (low- or high-doses) or without IFNγ/MOG and analyzed for 
the expression of MHC class II 48 h after stimulation. Numbers above bracketed lines in histograms indicate 
percent of MHCII+ microglia. (b) CD4+ cells were analyzed for the expression of GFP (Foxp3) after 7 days of 
co-culture with WT and MHCII-/- microglia. Numbers above bracketed lines in histograms indicate percent 
Foxp3EGFP+ cells. Data are representative of three separate experiments. Red arrows indicate days of analysis. 
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class II. Experiments with MOG-specific CD4+ T cells revealed that independent of the 
stimulation level, co-culture with MHCII-/- microglia did not result in induction of Foxp3+ 
regulatory T cells (7.17% under low-dose treatment), as did low-dose activated WT microglia 
(44.6%, Fig. 3.12 b). 
In complementary experiments we analyzed Foxp3+ regulatory T cells from 2D2 mice before 
and after co-culture with microglia for MOG-transgenic TCR defined by Vβ11 and Vα3.2, to 
exclude non-antigen specific induction of Treg cells. Analysis of Foxp3+ regulatory T cells, 
here identified by intracellular Foxp3 staining, revealed 66.3% Vβ11+ Treg cells before and 
71% Vβ11+ Treg cells after co-culture (Fig. 3.13 a), indicating that microglia induced Treg 
 
Fig. 3.13 Activated microglia induce antigen-specific Foxp3+ regulatory T cells. 
(a) CD4+ T cells were intracellularly stained for Foxp3+ and analyzed for the expression of Vβ11 and Vα3.2 
before (left dot plot) and after (right dot plot) co-culture with low-dose activated microglia. Numbers in rectangle 
gates indicate percent of Vβ11+ cells. (b) IFNγ activated microglia were pulsed with MOG (left) or MBP (right) 
before co-culture. MOG-specific CD4+ cells were analyzed for the expression of GFP (Foxp3) after 7 days. 
Numbers in left quadrants indicate percent of Foxp3+ cells. Red arrows indicate day of analysis. 
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display preferentially a MOG-specific TCR. In a second set of experiments, we pulsed IFNγ 
activated microglia with a different peptide, which is not recognized by the 2D2 transgenic T 
cell receptor, such as myelin basic protein (MBP). Co-culture of MOG-specific CD4+ T cells 
and low-dose (IFNγ/MBP) activated microglia did not result in induction of Foxp3+ regulatory 
T cells (4.5%) in contrast to MOG pulsed cultures (39%, Fig. 3.13 b). Together, these results 
demonstrate that microglia require MHC class II for effective antigen presentation, leading to 
preferential induction of Foxp3+ regulatory T cells when pulsed with low doses of IFNγ and 
respective antigen. 
3.2.2 Levels of co-stimulatory molecules contribute to tolerogenic phenotype of 
microglia 
CNS microglia up-regulate MHC class II and co-stimulatory molecules (e.g. CD40, CD80, 
and CD86) as a sign of activation in inflammatory diseases such as MS127,128. To further 
characterize the dose-dependent activation of microglial cells following IFNγ and antigen 
stimulation, we analyzed the regulation of these co-stimulatory molecules 48 h after 
treatment. Up-regulation of CD40 and CD86 significantly differed in low-dose and high-dose 
treated microglial cultures (Fig. 3.14 a, b). CD40 expression was 3-fold lower in low-dose 
cultures when compared to high-dose treated microglia (Fig. 3.14 a). Similarly, in low-dose 
stimulated cultures CD86 expression was 2-fold reduced compared to high-dose treatment 
(Fig. 3.14 b). Interestingly, IFNγ/MOG treatment, independent of its concentration had no 
 
Fig. 3.14 Microglia differentially regulate level of co-stimulatory molecules. 
Microglia were analyzed 48 h after IFNγ/MOG stimulation for mRNA expression of (a) CD40 (n = 3), (b) CD86 
(n = 3-4) and (c) CD80 (n = 3-4). Expression levels were normalized to the housekeeping gene Hprt (mean ± 
SEM, Student’s t test). 
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effect on CD80 expression (Fig. 3.14 c). This might indicate, that moderate levels of CD40 
and CD86 expression contribute to the tolerogenic phenotype of microglia that preferentially 
induce regulatory T cells. 
3.2.3 CD40-Ligand (CD40L) studies 
A recent study reported anti-CD40L treatment (anti-CD154 mAb) to selectively inhibit 
proliferation of effector T cells, but not CD4+CD25+ Treg cells in vitro, allowing the latter to be 
expanded129. We therefore co-cultured high-dose activated microglia with CD4+ T cells in the 
presence of anti-CD40L. However, the percentage of Foxp3+ Treg was not affected by the 
presence of anti-CD40-Ligand (6.4%) compared to high-dose control (5.5%) after 7 days of 
co-culture (Fig. 3.15). In contrast, blocking CD40 using CD154 (CD40-Ligand) resulted in a 
decrease of CD25+ cell population, indicating, that overall CD4+ T cell activation was affected 
(Fig. 3.15). In addition, overall T cell numbers markedly decreased in co-cultures 
supplemented with CD40L (data not shown). 
 
 
Fig. 3.15 The role of CD40/CD40L interaction in Treg proliferation. 
Microglia cultures were stimulated with high-dose IFNγ/MOG (100 U/ml IFNγ/ 10 µg/ml MOG) and co-
cultured with CD4+ T cells in the presence of CD40-Ligand antibody (anti-CD154, 40 µg/ml). Dot plots are 
showing CD25 staining and Foxp3EGFP expression with numbers in quadrants indicate percent of CD4+ gated 
cells. Data are representative of three independent experiments. 
3.2.4 Microglia secrete IL-10 particularly under low-dose conditions 
As previously reported interleukin-10 (IL-10) is produced in microglia-T cell co-cultures (see 
also CBA data from Fig. 3.4). In the periphery type II monocytes reveal anti-inflammatory 
properties characterized by enhanced secretion of IL-10106. We therefore analyzed the 
regulation of IL-10 gene expression in microglia following IFNγ/MOG stimulation. The 
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addition of low-dose stimuli resulted in a significant up-regulation of IL-10 compared to 
control (mean 9.6-fold ±1.8, Fig. 3.16 a), whereas high levels of IFNγ/MOG only showed a 
minor increase in IL-10 mRNA production (mean 2.7-fold ±1.2, Fig. 3.16 a). Finding IL-10 
mRNA levels exclusively up-regulated under low-dose conditions was consistent with IL-10 
protein production analyzed by ELISA (Fig. 3.16 b). These findings indicate a potential role 
for IL-10 in microglia-mediated induction of regulatory T cells and raised the question 
whether the addition of IL-10 to inflammatory microglia would help to reverse their 
phenotype. 
 
 
Fig. 3.16 IL-10 production by microglia cells. 
a) Microglia were stimulated and analyzed for mRNA expression of IL-10 (n = 3, mean ± SEM, Student’s t test). 
Expression levels were normalized to the housekeeping gene Hprt. b) Supernatants were collected and analyzed 
for IL-10 protein levels (ELISA, n = 3, mean ± SEM,**p<0.01, 1-way ANOVA). 
3.2.5 IL-10 rescues regulatory T cell response 
Because IL-10 is known to affect antigen presentation via modulation of IFNγ-induced MHCII 
molecule expression130, we investigated microglial MHCII expression after combined 
treatment of high-dose IFNγ/MOG and different doses of recombinant IL-10, ranging from 
0.2 ng/ml to 20 ng/ml IL-10 (Fig. 3.17 a). Increasing levels of IL-10 resulted in a dose-
dependent suppression of microglial MHCII expression. Notably, we found the combination 
of high-dose IFNγ/MOG and 2 ng/ml IL-10 corresponding to low-dose levels of MHCII 
expression (24.5%, Fig. 3.17 a). We therefore used 2 ng/ml IL-10 combined with high-dose 
IFNγ/MOG treatment for analyzing CD4+ T cell response in microglia-T cell co-cultures. 
Surprisingly, this combination prevented the differentiation of effector T cells and strongly 
induced Foxp3+ Treg, in a frequency comparable to that of low-dose IFNγ/MOG stimulation 
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(32%, Fig. 3.17 b). These data demonstrate, that the pre-treatment with IL-10 rescues the 
regulatory T cell response in co-cultures with inflammatory (high-dose) activated microglia, 
and indicate a crucial role of IL-10 in inducing a regulatory microglia phenotype. 
 
 
Fig. 3.17 A role for IL-10 in modulating microglia phenotype and CD4+ T cell response. 
IFNγ stimulation of microglia was combined with addition of recombinant IL-10 before co-culturing them with 
CD4+ T cells. (a) Histograms show dose response curves of IFNγ induced MHC class II 48 h after stimulation 
inhibited by increasing levels of anti-inflammatory IL-10. Numbers above bracketed lines indicate percent of 
MHCII+ cells. Data are representative of four individual experiments. (b) Expression analysis of Foxp3+ Treg 
after 7 days in co-cultures treated with low-dose, high-dose and IL-10 (2 ng/ml) + high-dose IFNγ/MOG. 
Numbers above bracketed lines indicate percent of Foxp3EGFP+ cells. Data are representative of four separate 
experiments. 
3.2.6 IL-10 effects IFNγ-induced microglia activation 
To elucidate the effects of IL-10, that render high-dose activated microglia to mediate a 
regulatory T cell response, we investigated mRNA levels of high-dose IFNγ/MOG activated 
cells and compared them to high-dose plus IL-10 (2 ng/ml) stimulated microglia. Interestingly, 
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the regulation of the co-stimulatory molecules CD40, CD80 and CD86 was not affected (Fig. 
3.18). In turn, exogenous IL-10 resulted in a significant down-regulation of endogenous IL-10 
transcription, the chemokine CXCL10, also known as IP-10 and IFNγ inducible NO synthase 
(iNOS, Fig. 3.18). 
 
 
Fig. 3.18 IL-10 modulates microglia activation. 
Microglia cultures were analyzed 48 h after high-dose IFNγ/MOG and IL-10 (2 ng/ml) + high-dose IFNγ/MOG 
treatment for the mRNA expression of co-stimulatory molecules (CD40, CD80, CD86), anti-inflammatory IL-
10, IFNγ dependent activation marker (iNOS) and the chemoattractant IP-10/CXCL10 (n = 4-6, mean ± SEM, 
Student’s t test). Expression levels were normalized to the housekeeping gene Hprt. 
3.2.7 Microglial antigen presenting properties compared to professional APCs 
IFNγ activated microglia were shown to less efficiently prime naive T cells compared to 
professional dendritic cells (DC)73. Finding a microglia phenotype that specifically induced 
Foxp3+ regulatory T cells from naive precursors raised the question, how the regulatory 
efficiency of microglia differs from that of professional APCs. Therefore, we applied the same 
stimulations and co-culture conditions to bone marrow derived macrophages (BM-M) and 
dendritic cells (BM-DC) and analyzed MHCII expression after stimulation and the induction of 
Foxp3+ Treg cells after 7 days. As expected, the control level of MHCII expressing cells was 
strikingly increased in BM-M (Fig. 3.19 b, mean 15.3 ± 0.89%) and BM-DC (Fig. 3.19 c, 
mean 54.7 ± 3.46%) compared to microglia (Fig. 3.19 a). IFNγ/MOG stimulation further 
increased the percentage of MHCII+ cells up to 63.42% in BM-M (Fig. 3.19 b) and 86.36% in 
BM-DC (Fig. 3.19 c) cultures, respectively. Surprisingly, we found no significant differences 
between low-dose and high-dose stimulation conditions in BM-M and BM-DC cell subsets, 
indicating that microglial MHCII expression is lower but regulated more differentiated. 
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Low-dose activated BM-DC induced the largest pool of Foxp3+ Treg (49%, Fig. 3.19 d) from 
CD4+ T cells after 7 days of co-culture. Co-culture with low-dose activated BM-M resulted in 
induction of 34% Foxp3 expressing Treg, comparable to microglial cells (32%, Fig. 3.19 d). 
When stimulated with high-doses of IFNγ/MOG, the frequency of Foxp3+ Treg clearly 
decreased in all cell subsets. However, in contrast to high-dose activated microglia, BM-M 
and also BM-DC still induced a distinct frequency of Foxp3+ Treg cells (BM-M 26% and BM-
DC 33%, Fig. 3.19 d), respectively. These data reflect, that microglial activation is a finely 
tuned process balancing regulatory and inflammatory CD4+ T cell responses. 
 
 
Fig. 3.19 Antigen presentation and CD4+ T cell response of microglia and professional APC. 
Microglia, bone marrow derived macrophages (BM-M) and dendritic cells (BM-DC) were generated in vitro 
from C57Bl6/J mice. Microglia (a), BM-M (b) and BM-DC (c) were stimulated with low- and high-dose 
IFNγ/MOG and analyzed after 48 h for expression of MHC class II by flow cytometry. Data are presented as 
mean ± SEM with n = 4-15 using Student’s t test. (e) Flow cytometric analysis of CD25 and Foxp3 expression 
on CD4+ T cells co-cultured with respective APCs. Data are representative of two separate experiments. 
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3.2.8 Alternative ways to activate microglia cells 
Considering that stimulation with recombinant IFNγ worked well as a danger signal leading to 
up-regulation of antigen presenting molecules on microglia in vitro, we replaced recombinant 
IFNγ in our systems with Th1 cells or Th1 cell supernatant from WT mice. Therefore, we 
generated Th1 cells in vitro, harvested Th1 cells and supernatants on day 4-5 after 
preparation, stimulated microglia with a gradient of both and analyzed MHC class II 
expression after 48 h. Th1 cell titration ranged from 6 x 104/ml up to 2 x 106/ml, while Th1 cell 
culture supernatants were diluted stepwise down to 1:32. We observed that supernatants 
from activated Th1 cells induced MHC class II expression on microglia in a concentration-
dependent way (Fig. 3.20 a). Notably, cultures treated with the undiluted Th1 cell 
supernatants showed up to 50% MHCII+ microglia, whereas the 1:32 dilution resulted in only 
4.5% MHCII+ cells. MHCII+ microglia frequencies corresponding with low-dose IFNγ/MOG 
treated cultures were achieved with a 1:4 dilution of Th1 supernatant (24% MHCII+ 
microglia). In contrast, higher concentrations of Th1 cells on microglia (2 x 106/ml and 
1 x 106/ml) led to rather low MHCII+ frequencies (Fig. 3.20 b) and a massive loss of 
microglial cells was observed in parallel. The stimulation with around 1.25 x 105/ml Th1 cells 
resulted in MHCII+ frequencies similar to that of low-dose recombinant IFNγ treatment (Fig. 
3.20 b). In complementary experiments we stimulated microglial cells with substances 
already described or speculated to induce MHC class II on microglia in vitro, such as CpG 
DNA131, Hsp60, LPS132,133, poly I:C or necrotic astrocytes. However, with none of these 
substances microglial MHCII expression could be detected by flow cytometry. These data 
indicate that antigen presenting capacities of brain resident microglia are particularly 
regulated by type II interferons (primarily IFNγ). 
 
Fig. 3.20 Th1 cells and Th1 cell supernatant induce MHC class II expression on microglia. 
Flow cytometry analysis of MHC class II expression on microglia stimulated with a gradient of (a) Th1 cell 
supernatant (n = 3, mean ± SEM) or (b) Th1 cells (n = 3, mean ± SEM). Red arrow indicates day of analysis. 
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3.2.9 CD4+ T cell co-culture with adult microglia 
Analogues to co-cultures with postnatal microglia, we applied adult microglia in vitro to 
substantiate our findings. U. K. Hanisch provided the protocol for generating and culturing 
adult microglia from C57Bl6/J mice. Adult microglia were cultured on a postnatal, astrocytic 
layer in the presence of L929 cell conditioned media and harvested for CD4+ T cell co-culture 
assays 7 days later. Adult microglia were stimulated exactly the same way as postnatal 
microglia with different doses of IFNγ/MOG. 
Whereas unstimulated cells (Control) did not express MHCII, IFNγ/MOG stimulation induced 
MHCII on up to 81.5 ± 1.8% (Fig. 3.21 a, high-dose stimulation) of microglia. Low-dose 
stimulated adult microglia showed only marginal lower MHCII expression (75 ± 2.3%, Fig. 
3.21 a). Similar to postnatal microglia, adult microglia induced preferentially Foxp3+ 
regulatory T cells, when stimulated with tolerogenic doses of IFNγ/MOG (44%, Fig. 3.21 b). 
In contrast, co-cultures with high-dose activated adult microglia showed lower levels of 
Foxp3+ Treg induction, but still induced a distinct frequency (22%, Fig. 3.21 b) compared to 
postanatal microglia (Fig. 3.1 a, b). As a major difference, high-dose activated adult 
microglia did not evoke distinct CD25 expression on Foxp3- T cells. It remains unclear, 
whether this reflects incomplete activation of CD4+ T cells. 
Together this data indicate, that adult microglia strongly respond to IFNγ/MOG with up-
regulating MHCII and that adult microglia are able, similar to postnatal microglia, to induce 
Foxp3+ regulatory T cells under low-dose conditions. 
 
 
Fig. 3.21 Adult microglia induced T cell responses in vitro. 
(a) Adult microglia were analyzed 48 h after IFNγ/MOG stimulation for expression of MHC class II molecules 
by flow cytometry (n = 5, mean ± SEM, Student’s t test). (b) Flow cytometric analysis of CD25 and Foxp3 
(GFP) expressing cells after 7 days of co-culture with adult microglia. Data are representative of two individual 
experiments. 
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3.3 Results (III) – Potential in vivo implications of MHCII expression 
within the CNS 
This part aims at the influence of CNS MHCII expression on CD4+ T cell responses in a 
mouse model of brain injury. The entorhinal cortex lesion (ECL) model is widely used to 
study microglial activation and leukocyte infiltration after CNS injury. The model involves the 
stereotactical lesion of the perforant path, a myelinated fiber tract connecting the entorhinal 
cortex with the hippocampus, leading to anterograde degeneration of the hippocampus54. 
After ECL, myelin-specific T cells expand in draining lymph nodes, invade regions of 
degeneration but do not elicit autoimmune encephalomyelitis-like white matter damage. 
Inflammation in regions of degeneration, as it occurs in MS, seems to be tightly regulated 
and eventually kept under control after brain injury, implying active maintenance of immune 
tolerance54. We therefore used ECL to investigate whether antigen presentation properties of 
brain resident cells alter the CD4+ T cell response to CNS tissue damage. 
3.3.1 Enhanced CNS infiltration of CD4+ T cells and Foxp3+ Treg after ECL is 
prevented in MHCII-/- mice 
In preliminary experiments we demonstrated that among CNS infiltrating T lymphocytes 
detected after entorhinal cortex lesion (ECL), a model of sterile CNS injury, CD4+ T cells and 
especially CD4+Foxp3+ Treg cells significantly increased in number and frequency 14 days 
after the insult at the site of lesion. At the same time increased numbers of MHCII expressing 
Iba1+ cells were detected in the lesion site and in direct contact to Foxp3+ Treg cells (Stubbe, 
personal communication). We therefore asked whether CNS expression of major 
histocompatibility complex class II (MHCII) is required for accumulation of regulatory T cells 
in a model of non-inflammatory CNS lesion (ECL). To address this issue we operated MHC 
class II deficient mice (MHCII-/-), which received 2 x 107 CD4+ T cells from Foxp3EGFP reporter 
mice 1 day before ECL to reconstitute the CD4+ T cell compartment, and analyzed CD4+ and 
CD4+Foxp3+ T cells according to the gating strategy illustrated in Fig. 3.22. In contrast to the 
WT situation, we observed no significant CNS-infiltration of CD4+ lymphocytes in ipsilateral 
compared to contralateral hemispheres in MHCII-/- mice (Fig. 3.23 a). In line with that, 
ipsilateral numbers and frequencies of infiltrating CD4+Foxp3+ Treg cells were drastically 
reduced in MHCII-/- mice (Fig. 3.23 b and c) and did not differ between ipsi- and contralateral 
hemispheres. This indicates that the infiltration of CD4+ lymphocytes and the accumulation of 
Foxp3+ Treg cells at the site of CNS lesion is an active response of the adaptive immune 
system requiring antigen presentation via MHC class II. 
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3.3.2 Diminished Foxp3+ Treg cell recruitment after ECL in mice lacking MHCII 
specifically in the CNS 
To study the role of MHC class II restricted antigen presentation by CNS resident cells and 
its effect on CD4+Foxp3+ Treg cell recruitment and accumulation, we generated bone marrow 
chimeric mice (Fig. 3.24) deficient of MHCII exclusively in the periphery (MHCII-/- → WT) or 
in the CNS (WT → MHCII-/-). As MHCII WT control we used Foxp3EGFP mice reconstituted 
with Foxp3EGFP bone marrow referred to as WT → WT chimeric mice (Fig. 3.24). 
Following engraftment, blood phenotyping revealed that B220+ B cells of WT mice 
reconstituted with MHCII-/- bone marrow (MHCII-/- → WT) expressed almost no MHC class II 
(1.2%), whereas WT → MHCII-/- chimeras expressed with 96.1% MHCII already wild-type 
 
Fig. 3.22 Gating strategy for flow cytometry analysis of CNS infiltrating leukocytes. 
 
 
Fig. 3.23 Foxp3+ Treg cells infiltrate the lesioned CNS of WT but not MHCII-deficient mice. 
Absolute numbers of infiltrating CD4+ (a) and CD4+Foxp3+ Treg cells (b) 14 days after ECL in WT vs. MHCII-/- 
mice analyzed by flow cytometry (n = 7-9, mean ± SEM, Student’s paired t test). (c) Flow cytometry of 
Foxp3EGFP frequency in CD4+ T cells, comparing ipsilateral and contralateral hemispheres of WT and MHCII-/- 
mice (n = 7-9, mean ± SEM, Student’s paired t test). 
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WT → WT levels (96.5%, Fig. 3.25 a). Typing results are summarized in Fig. 3.25 b and 
support that WT → MHCII-/- chimeras harbor a normal peripheral APC compartment (MHCII 
expression on B cells, macrophages and DCs), but lack MHCII expression on CNS resident 
cells. 
While WT → WT and WT → MHCII-/- chimeras recovered well after reconstitution, MHCII-/-
 → WT chimeric mice developed symptoms of ulcerative colitis (e.g. diarrhea and prostrated 
posture) 7-8 weeks after reconstitution and died within a few days after the first symptoms. 
 
Fig. 3.24 Experimental setup for generating bone marrow chimeras. 
Following lethal irradiation mice were transplanted with respective bone marrow depleted of CD90.2+ (Thy1.2) 
cells and allowed to reconstitute for 6-8 weeks before they were subjected to blood phenotyping. 
 
 
Fig. 3.25 Blood typing of MHCII bone marrow chimeras. 
Lymphocytes isolated 6 weeks after reconstitution from the blood of chimeric mice were subjected to flow 
cytometry (a) Dot plots showing MHCII staining of B220+ cells of all three groups. Numbers beside quadrant 
gates indicate CD45R/B220+MHCII+ cells. Dot plots are representatives of 8-18 mice per group of chimeras 
summarized in (b) as MHCII+ expressing cells in % of B220+ cells (mean ± SEM). 
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Since Marguerat et al. already described these findings as a murine radiation-induced colitis 
model134, we tried to overcome immunopathology by applying different strategies. We 
repeated the generation of MHCII-/- → WT chimeras with prolonged antibiotic treatment 
(Baytril®) on one hand or administered regulatory T cells from congenic (Thy1.1) mice i.v. on 
the day of reconstitution to enlarge the pool of protective T lymphocytes on the other hand. 
However, none of these strategies worked out and only WT → WT and WT → MHCII-/- 
chimeric mice were subjected to entorhinal cortex lesion (ECL) and analyzed 14 days later 
according to Fig. 29. Notably, both groups received 2 x 107 CD4+ T cells from Foxp3EGFP 
reporter mice one day before they were subjected to ECL surgery. 
 
We analyzed the composition of brain infiltrating leukocytes, cervical lymph nodes (CLN) and 
blood with special interest in CD4 and Foxp3 expressing lymphocytes. We compared 
infiltrated numbers of CD45high cells ipsilateral (Fig. 3.27 a) from WT → WT (mean 
5221 ± 1182 cells) and WT → MHCII-/- mice (mean 4802 ± 540 cells) and found no significant 
difference in CD45high cell number, indicating that local MHCII expression is not crucial for 
overall leukocyte infiltration. In contrast, the number of CD4+ cells were significantly 
decreased in WT → MHCII-/- mice (mean 339 ± 41 cells) compared to WT → WT animals 
(mean 619 ± 134 cells) suggesting that mice lacking MHCII in the CNS are no longer able to 
selectively recruit CD4+ T cells to the lesion site (Fig. 3.27 b). In line with that, we also found 
the number of Foxp3 expressing Treg cells (Fig. 3.27 c) to be diminished in WT → MHCII-/- 
 
Fig. 3.26 Experimental setup for inducing CNS injury (ECL) in MHCII chimeric mice. 
EC = Entorhinal Cortex, DG = Dendate Gyrus, PP = Perforant Path, CA1-3 = Cornu Ammonis, CLN = Cervical 
Lymph Nodes. 
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mice (mean 106 ± 19 cells) versus WT → WT animals (mean 169 ± 43 cells). Related to 
overall infiltrated leukocytes, we observed that significant less Foxp3+ Treg cells per CD45high 
leukocyte were recruited to the ipsilateral hemispheres of WT → MHCII-/- versus WT → WT 
chimeras (Fig. 3.27 d), implying an potentially less regulatory CNS infiltrate in mice lacking 
MHCII specifically in the brain. In addition, we compared Foxp3+ Treg frequencies of the 
brain with that of CLN and blood but found no longer a specific increase of Treg at the lesion 
site in WT → MHCII-/- (Fig. 3.27 e). We therefore speculate, that MHCII expression in the 
CNS is required to selectively recruit more CD4+ cells, containing a large proportion of 
Foxp3+ Treg cells, to the sites of CNS injury. Thus, MHCII expressed on brain resident cells 
renders the profile of the infiltrating leukocyte population more regulatory in the model of non-
inflammatory ECL. 
 
 
Fig. 3.27 Analysis of CNS infiltrating leukocytes in MHC class II chimeric mice. 
CNS infiltrating leukocytes as well as CLN and blood cells from WT → WT and WT → MHCII-/- mice were 
analyzed by flow cytometry showing absolute numbers of (a) CD45high, (b) CD4+ and (c) Foxp3+ Treg cells and 
(d) the ratio of Foxp3+ Treg per infiltrating CD45high leukocyte (n = 8-18, mean ± SEM, Student’s t test). (e) 
shows the ratio of Foxp3+ Treg in % of CD4+ T cells comparing CNS infiltrating cells to those from CLN and 
blood (n = 8-18, mean ± SEM, Student’s paired t test). 
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4 Discussion 
The trafficking of immune cells into the central nervous system is tightly controlled to 
maintain immune homeostasis and optimal brain function135. While leukocyte extravasation 
into the CNS is a key event in the pathogenesis of acute or chronic inflammatory neurological 
diseases136, CNS immune surveillance is central to protect against cerebral infection135. 
Immune cells of peripheral origin, such as T cells, macrophages and dendritic cells, but also 
brain resident microglia carry out routine CNS immune surveillance. Microglia, the major 
immune competent cells of the brain, continuously survey their environment for any stranger 
or danger signals indicating neuronal disturbances. Lacking cell surface expression of MHC 
class II and co-stimulatory molecules under steady state conditions, microglia are often 
referred to as non-professional antigen presenting cells. The regulation of microglia antigen 
presenting capacity and its effect on controlling T cell responses was the subject of 
investigation in this thesis. The main findings therein are, that 
a) depending on their activation level, microglia mediate the differentiation and 
proliferation of Foxp3+ Treg or Foxp3- effector T cells, 
b) microglia-induced Treg cells are stable and functionally active in vitro and in vivo, 
c) microglia-mediated Treg induction is MHCII and antigen-dependent, 
d) microglia phenotypes control CD4+ T cell responses by regulating levels of co-
stimulatory molecule expression and IL-10 secretion. 
4.1 The brain – From the T cell’s point of view 
This study describes the role of microglia phenotypes in modulating CD4+ T cell responses 
based on an in vitro co-culture assay. However in vivo, CD4+ T cell extravasation into the 
CNS and microglial activation are the major prerequisites for microglia to serve as antigen 
presenting cells and modulate CD4+ T cell responses. Since the resulting immune response 
of microglia – T cell interaction in the in vivo situation also depends on the nature of CNS 
infiltrating CD4+ T cells, the following section briefly summarizes how T cells gain entry into 
the CNS, their routes of entry and in which state they are behind the barriers distinguishing 
between routine immune surveillance and CNS pathology. 
There is rising evidence for continuous leukocyte trafficking into the healthy CNS across the 
endothelial BBB via the perivascular space or across the blood-cerebrospinal fluid barrier 
(BCSFB) formed by epithelial cells of the choroid plexus12,13,137. Studies in different models 
proof that in the absence of inflammation and independent from antigen-specificity, highly 
activated but not resting T cells can migrate across the vascular walls of the BBB6,138–140. 
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Conflicting findings come from the group of Joan M. Goverman showing that in Rag−/− MBP 
TCR transgenic mice the vast majority of T cells in the healthy CNS exhibit a naive 
phenotype141. They speculated that these CNS specific T cells undergo tolerance induction in 
situ directly in the CNS and therefore do not trigger autoimmunity141. The functional state and 
lineage commitment versus plasticity of infiltrating CD4+ T cells is of particular importance for 
discussing in vivo implications of microglia-mediated induction of Foxp3+ Treg cells (see 
section 4.3.1). 
In the current model of immune surveillance, CNS patrolling leukocytes are thought to screen 
antigen-presenting cells in the perivascular space. Besides microglial cells, meningeal and 
perivascular macrophages, dendritic cells and choroid plexus macrophages are strategically 
localized adjacent to the brain barriers and capable of antigen presentation via MHC 
molecules13, implying that CNS patrolling CD4+ T cells can encounter microglia not only in 
the deep brain parenchyma but also in the perivascular space. T cells do not seem to further 
migrate across the glia limitants into the parenchyma in the absence of antigen-triggered re-
activation140, indicating that immunosurveillance is confined to perivascular CNS 
compartments12. Using intravital microscopy during passive EAE, Bartholomäus and 
colleagues showed that in the absence of their cognate antigen, OVA-specific T cells 
crossed the vessels but formed only transient contacts with perivascular/meningeal APCs 
without up-regulation of activation markers or inflammatory cytokines140. In contrast, 
transferred MBP-specific T cells formed diverse and often long-lasting contacts, became re-
activated and migrated deeply into the CNS parenchyma. These observations suggest that 
continuous antigen-specific re-activation is necessary for encephalitogenic T cells to enter 
the CNS tissue in the absence of inflammation. 
In CNS pathology, T cells become re-activated in perivascular or subarachnoid spaces and 
will trigger an inflammatory response that leads to up-regulation of additional traffic signals 
on BBB and BCSFB12. Recruitment of more and more immune cells together with cytokine 
and protease secretion will lead to degradation of the glia limitants. As soon as the blood-
brain barrier is compromised a large number of inflammatory cells gain entry to the 
parenchyma and initiate autoimmune CNS inflammation. In contrast to EAE, which models 
severe CNS inflammation, the model of entorhinal cortex lesion (ECL) reflects a steril, non-
inflammatory brain lesion leading to axonal degeneration54. Such lesions lead to activation of 
endothelial cells resulting in a loss of tight junction integrity and formation of transendothelial 
cell channels142,143. In addition to the passive leukocyte entry due to BBB breakage, myelin-
specific T cells expand in draining lymph nodes, invade injured regions and mediate 
secondary degeneration58,60. However, brain injury does not lead to destructive autoimmunity 
implying that mechanisms exist that control T-cell dependent immune responses after CNS 
trauma119. 
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In sum, T cells can actively migrate into the healthy CNS during routine immune surveillance, 
passively enter the CNS after BBB disruption or are recruited in the context of CNS 
inflammation. Continuous antigen-specific re-activation of T cells is a critical step during the 
initial T cell entry in the absence of inflammation as well as for their migration deep into the 
parenchyma. This is where microglia enter the stage. 
4.2 Infiltrating T cells – From the microglial side 
Professional APC, that constitutively express MHCII, are missing in the healthy CNS. 
However brain resident microglia have the potential to migrate to regions of tissue damage, 
undergo proliferation, increase phagocytic activity, secrete cytokines and chemokines and 
up-regulate molecules for effective antigen presentation28. Assuming that microglial cells do 
not actively leave the injured CNS to present antigen in draining lymph nodes144, the 
microglia-T cell interaction takes place directly behind the brain barriers and in the 
parenchyma.  
We hypothesized that microglia can do both, act as inducer or amplifier of pro-inflammatory 
CD4+ responses as well as inducer of regulatory mechanisms. This hypothesis was 
formulated based on previous findings from looking at either the T cell or the APC side. 
Firstly, in parallel to microglial activation, entorhinal cortex lesion, which models mild 
inflammatory events, results in infiltration of self-antigen specific T cells that do not initiate 
MS-like destructive immunity. Quite the contrary is observed; when subjecting lesioned mice 
to EAE, these animals show reduced disease severity, suggesting long-term tolerogenic 
effects119. Moreover, microglia properties for limiting CNS inflammation or regulating immune 
responses have been discussed145. Secondly, experiments by our group could demonstrated 
that 14 and 30 days after ECL, Foxp3+ regulatory T cells accumulate in the brain with 
increased frequencies compared to peripheral organs (Stubbe, unpublished). 
Immunohistology of ECL brains revealed the presence of MHC class II expressing Iba1+ 
microglia in contact to Foxp3+ regulatory T cells in the CNS parenchyma. Thirdly, the 
peripheral induction of Foxp3+ Treg by professional, peripheral APC, such as 
“subimmunogenic” primed dendritic cells105 or type II monocytes106, have been described to 
specifically rely on their activation-dependent phenotype. To test whether microglia, the 
immune sentinels of the brain, can mediate conversion of naive CD4+ T cells into regulatory, 
Foxp3+ expressing T cells, a microglia – T cell co-culture was established. 
4.3 Microglia and T cells in co-culture 
Microglia are non-professional APC that lack MHC class II molecules in their resting state, 
but constitutively express the IFNγ receptor (IFNγR). IFNγ is the most prominent inducer and 
amplifier of cytotoxic, phagocytic, and antigen-presenting features of microglia146. Aside from 
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infiltrates of IFNγ-producing T cells in MS disease or EAE, increased IFNγ expression in the 
brain has been reported following stroke112,147,148 and other neuropathological conditions such 
as nerve injury149. T cells (CD4+ and CD8+ phenotype) and natural killer (NK) cells are the 
main sources of IFNγ, although neurons and microglia themselves have been shown to 
contribute to CNS IFNγ levels150,151. IFNγ signals through binding to the IFNγR, initiating the 
classical JAK-STAT pathway and leading to transcription of over 200 interferon responsive 
genes152,153. In microglia, IFNγ induces or regulates MHC class I and II molecules125, co-
stimulatory molecules (CD80/86), leukocyte function-associated molecule 1 (LFA-1), LPS 
receptor (CD14), Fc and complement receptors, changes in the proteasome composition, as 
well as release of cytokines (TNFα, IL-1, IL-6), complement (C1q, C2, C3, C4), chemokines 
and NO146. Because IFNγ was proven particularly effective as an inducer of MHC 
molecules154, recombinant IFNγ was used in this study to induce molecules needed for 
efficient antigen presentation on microglia. In combination with the brain specific MOG 
antigen, we were able to analyze TCR-driven differentiation of purified MOG-specific CD4+ T 
cells mediated by microglial cells. An experimental set up was established, that 
encompassed IFNγ stimulation for 24 h following MOG-priming for another 24 h before 
purified CD4+ T cells were applied on top of the microglial monolayer. This timeline allows 
activation-dependent expression of microglial surface molecules as well as cytokine and 
chemokine synthesis before T cell engagement. 
For the first time this study proves that brain-derived microglia have the ability to induce 
Foxp3+ regulatory T cells in vitro (Fig. 3.1 a). Foxp3+ Treg induction was shown to be 
antigen-specific and MHCII-dependent and, together with the negative correlation between 
dosage of stimuli/antigen and the Foxp3+ frequency, prompted us to further study microglial 
plasticity on the one hand and microglia-mediated T cell differentiation on the other hand. 
The underlying hypothesis was that the high number of Foxp3+ Treg under low-dose 
conditions is a result of a distinct regulatory microglia phenotype in combination with low 
levels of antigen presented by these cells.  
4.3.1 The T cell side of co-culture 
The differential effect of microglia-activation on CD4+ T cell dynamics, their cytokine pattern 
and the suppressive function of microglia-induced Foxp3+ were studied within the first part of 
this thesis. 
Low-dose treated microglia revealed a very reproducible Treg kinetic with the first increase in 
Foxp3+ cells showing up 3 days after the beginning of co-culture (Fig. 3.3). A similar lag 
period in single cell Foxp3 protein expression was reported for TGF-β-mediated induction of 
Treg in vitro155. The authors therefore suggest that complex combinatorial or sequential 
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signals are involved in TGF-β-mediated Foxp3 induction. In turn, CD25+Foxp3- effector T 
cells started to increase already from the very first day of co-culture, independent from 
whether microglia have been low-dose or high-dose activated (Fig. 3.3). Interestingly, kinetic 
analysis of both stimulation conditions exhibited a rapid increase of CD25+Foxp3- T cells 
peaking on day 4, whereas Foxp3+ Treg induction revealed a linear progression until day 7. 
Notably, also low-dose primed microglia induced a population of CD25+Foxp3- effector T 
cells early during co-culture, before and while Foxp3+ expression was increased. The 
subsequent questions, whether these CD25+Foxp3- cells functionally differ from those 
induced under high-dose treatment, if they signal back on microglial cells thereby facilitating 
Treg conversion or proliferation, or if CD25+Foxp3+ arise from this population led us to 
analyze a set of cytokines produced during co-culture. 
Monocyte chemoattractant protein-1 (MCP-1, CCL2), a member of the β-chemokine 
subfamily, was highly secreted in co-cultures when microglia were pre-exposed to IFNγ, with 
only minor changes in regard to low- or high-dose exposure (Fig. 3.4). Being involved in the 
activation and directional migration of leukocytes to inflammatory sites, early MCP-1 
expression is reported in MS lesion156, EAE parenchymal cells157 or trauma brains158. A study 
on human fetal microglia revealed that IFNγ in concert with CD40-CD40L interaction induces 
MCP-1 expression in microglia mediated by the ERK1/2 MAPK pathway159. Because in our 
set-up IFNγ was removed from the system before CD4+ T cell – microglia interaction (CD40-
CD40L ligation), we suggest that a certain timeframe exists by which both signals can act in 
concert to induce MCP-1 secretion. Alternative sources of CNS MCP-1 are astrocytes and 
infiltrating monocytes160,161. There is emerging evidence, that activated microglia not only 
differentially affect the recruitment of Th1 and Th2 cells by secreting respective chemokines 
(MIP-1α versus MCP-1)162, but also play a role in polarizing Th1 versus Th2 re-activation 
response by cytokine secretion, thereby potentially balancing the outcome of CNS immanent 
immune responses71. How MCP-1 influences CD4+ T cell polarization is discussed by Luther 
and Cyster163. The authors summarize that MCP-1 ligation to its receptor CCR2 promotes 
Th2 effector cell development by acting on APCs (reduction of IL-12) as well as the CD4+ T 
cell side (production of IL-4)163. Notably, we did not detect any IL-4 in our co-cultures, but 
large amounts of the Th2 cytokine IL-13 when stimulated with high-dose IFNγ/MOG (Fig. 
3.4). The role of anti-inflammatory IL-13 on microglial cells in vitro was studied by Yang et 
al.164 who reported, that IL-13 induces death of LPS activated microglia and suggested a 
Fas/FasL and NO independent mechanism. However, we did not observe significant 
changes in the number of microglia between the different co-culture conditions (data not 
shown). In addition, the IL-13 levels detected in high-dose treated co-cultures were 20-times 
less compared to the concentrations used by Yang and colleagues164. That microglia are 
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able to stimulate and re-stimulate Th2 responses, thereby contributing to a local regulatory 
circuit for the inhibition of Th1 responses has been shown before by the group of Francesca 
Aloisi165. However, it was surprising to find not only Th2 cytokines, but also Th1 (IFNγ) and 
Th17 (IL-17) cytokines being produced during culture of high-dose treated microglia with 
naive CD4+ T cells. This led us to speculate about effector T cell plasticity specifically 
induced by microglia. In line with that, intracellular cytokine staining revealed IFNγ/IL-17 
double-positive cells (Fig. 3.5). In sum, we observed a very distinct change in the effector T 
cell cytokine profile from co-cultures pre-treated with low-dose compared to high-dose 
IFNγ/MOG. The profile indicates high expression of IL-13, IL-17, IFNγ, IL-6 under high-dose 
conditions, while IL-23, IL-1β and IL-4 could not be detected at all. Mouse Th17 cell 
development in parallel with Foxp3 down-regulation mediated by IL-6 has been studied in 
detail166. Recent observations show that in the presence of IL-6, TGF-β is able to drive 
RORγt up-regulation and the subsequent induction of IL-17 cells. The contribution of TGF-β 
on Foxp3 and regulatory T cell induction as well as on Th17 cell induction depending on the 
microenvironment reflects the developmental plasticity of T helper cell responses. Recent 
reports suggest, that IL-23 is needed for terminal differentiation into Th17 cells as well as for 
their pathogenicity167,168. Taken together, high-dose IFNγ/MOG treatment induces a microglia 
phenotype, that mediates an effector T cell response that can not be simply assigned to one 
polarization, but resembles a mixture of Th1, Th2 and Th17 specific cytokines. In turn, low-
dose co-cultures exhibiting high Foxp3+ Treg levels, revealed expression of the above 
mentioned cytokines at very low levels or are completely absent, whereas IL-10 expression 
was increased. Both microglia and Foxp3+ Treg cells are known to secrete anti-inflammatory 
IL-10, therefore a contribution of both to the IL-10 level cannot be ruled out.  
In vivo different T helper cell subsets have been identified to contribute to the pathogenesis 
of EAE and MS169. Besides the Th1 phenotype, which was very potent in inducing EAE, also 
the adoptive transfer of in vitro generated Th17 or Th9 cells specific for MOG antigen was 
shown to induce CNS autoimmunity with different pathological phenotypes170,171. The specific 
cytokines produced by these distinct encephalitogenic T helper cell subsets might well 
account for pathological heterogeneity in MS patients170. Recently several modes of plasticity 
of T cell subsets have been described172, including iTreg to Th17 and vice versa173, Th17 to 
Th1174 or Th2 to Th1175. Surprisingly, even under severe inflammatory conditions, such as 
MS disease or its animal model EAE, brain infiltrating Th cell subsets display substantial 
plasticity169. A recent study suggests that fate decisions of Th17 cells are shaped by different 
inflammatory conditions allowing them to switch from IL-17 to IFNγ production176 in the 
chronic EAE model. Conversely, Th1 cells can also convert into IL-17/IFNγ double producers 
during the development of EAE, strongly questioning IL-17 expression as definition of an 
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end-stage T helper cell subset177. These data suggest that the tissue or cytokine milieu to 
which these cells migrate determines their final differentiation even after commitment to a 
specific T helper cell lineage. 
Together with our own observations these reports strengthen the importance of the 
microenvironment on T cell differentiation, commitment and stability, especially when 
leukocytes enter an immunoprivileged site such as the CNS, where continuous re-activation 
is a critical step. 
 
Two different approaches were applied to solve the question, whether elevated frequencies 
of Foxp3+ cells result from proliferation of pre-existing Treg cells or from the conversion of 
naive precursors into de novo induced Foxp3+ Treg cells. Using CD4+CD25-Foxp3- cells as 
starting population, Foxp3+ cells could be readily detected after co-culture with differentially 
activated microglial cells indicating de novo induction of Treg cells from CD4+ precursors 
(Fig. 3.6). However, Foxp3-negative regulatory T cells (iTr35178, Tr1179 or Th3 cells) are not 
depleted in this model. The frequency of Foxp3+ cells in the de novo set-up was markedly 
reduced compared to co-cultures with total CD4+. Because of that, we set up a second set of 
experiments analyzing proliferation of Treg (Foxp3+) and effector T cells (Foxp3-) from 
microglia co-cultured with total CD4+ cells. Interestingly, in low-dose primed co-cultures only 
Foxp3+ cells underwent proliferation, whereas Foxp3- cells did almost not (Fig. 3.7). In 
contrast, 6 days after co-culture high-dose treatment resulted in both, Foxp3- and Foxp3+ cell 
proliferation to a similar extent. These data suggest that both, de novo induction and 
subsequent proliferation of Treg cells lead to accumulation of Foxp3+ cells under low-dose 
conditions, indicating potentially different mechanisms by which microglia contribute to 
immune regulation. This is in line with in vivo and in vitro data from Kretschmer and 
colleagues, who reported that under “subimmunogenic” conditions (low-level antigen and 
lack of co-stimulation) peripheral DCs efficiently induce de novo Treg cells, but observed 
reduced conversion and high proliferation when highly activated DCs were present105. This 
view is further supported by the kinetic analysis of Foxp3+ Treg frequencies over a 7 day 
period of co-culture. Already 3 days after being co-cultured with activated microglia, Foxp3+ 
frequencies started to increase (Fig. 3.3), while proliferation was not observed (data not 
shown), suggesting conversion of naive into regulatory T cells at that specific time point. In a 
second step, cell proliferation was observed in low-dose stimulated co-cultures on day 5 (not 
shown) and 6, but restricted to the Foxp3+ population. Again, high-dose stimulated microglia 
are found to induce extensive T cell proliferation but considerably less conversion into 
Foxp3+ Treg, underlining the inverse relationship between proliferation and Treg 
conversion105. This also raised the question what factors drive proliferation exclusively in 
Foxp3+ Tregs. Several studies describe IL-2 driven proliferation of Foxp3+ regulatory T 
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cells180–182. While the IL-2 receptor (IL-2R) is expressed on mouse and human microglia183, 
IL-2 itself is not produced by microglial cells. Activated, non-regulatory T cells are the cellular 
source of IL-2. One possible explanation is that the population of CD4+CD25+Foxp3- cells 
induced during the early days of co-culture (see days 1-4 of kinetic experiments), secrete IL-
2, which than leads to expansion of de novo induced and pre-existing Foxp3+ regulatory T 
cells. High frequencies of Foxp3+ (resulting from de novo conversion) in low-dose activated 
co-cultures in turn suppress proliferation of CD25+Foxp3- effector cells. Other studies link 
high CD86 expression on APC with Treg proliferation184, that will be further discussed when 
microglial phenotypes are dissected. Notably, we did not detect any IL-4 in our set-up, 
excluding IL-4 driven Treg proliferation as documented by Xu et al.185. An additional 
explanation involves the signaling from de novo induced Treg back to the microglial 
cells112,186. 
The suppressive activity of microglia-induced Treg cells was proven in vitro, where sorted 
Foxp3-GFP+ from low-dose co-cultures efficiently suppressed proliferation of 
encephalitogenic effector T cells up to a ratio of 1:50 (Fig. 3.9). To functionally test microglia-
induced Treg in a clinical relevant model, we adoptively transferred CD4+CD25+ Treg cells 
purified from low-dose stimulated co-cultures into Bl6/J recipients one day before MOG 
immunization (Fig. 3.10). In this model of autoimmunity, autoantigen-specific T cells are 
primed in the periphery (draining LNs), infiltrate the CNS and result in progressive paralysis 
starting 10-12 days after immunization187. In contrast to PBS control mice and mice 
transferred with CD4+CD25+ cells (nTreg) isolated from the spleens of naive 2D2 mice, 
microglia-induced Treg ameliorated disease severity. The administration of microglia-induced 
Treg during priming did not delay onset or peak of disease, but significantly decreased 
disease severity and mortality rate, suggesting that microglia-induced Treg interfere with 
disease progression. Since Thomas Korn and colleagues found that CNS-derived 
autoantigen-specific effector T cells isolated at the peak of disease cannot be suppressed in 
vivo and in vitro by either CNS-derived or peripheral antigen-specific Treg cells, disease 
amelioration mediated by transfer of microglia-induced Treg might already take place in the 
periphery (draining LNs). Surprisingly, in our study nTreg isolated from naive MOG TCR 
transgenic animals failed to suppress EAE disease scores. This is in apparent contrast to 
findings of Kohm et al., who reported significant protection from the development of clinical 
EAE in Bl6/J mice when transferring CD4+CD25+ nTreg fom WT animals115. However, the 
authors transferred 2 x 106 cells, a considerable greater number of cells than used in our 
experimental set-up (500.000 cells per mouse). To rule out the potential effect of different 
TCR specificity in both set-ups, we included nTreg from BL6/J WT animals in active EAE, but 
observed no EAE disease protection in control to PBS treated mice (data not shown). This 
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data-set illustrates the potential of relatively small numbers of microglia-primed, MOG-
specific Treg to ameliorate MOG EAE. 
How epigenetic processes regulate cell lineage differentiation has already been shown for 
Th1 and Th2 cells, where histone and covalent DNA modifications lead to converse pattern 
of gene activation and silencing188. Recent studies now identified a Treg-specific 
demethylated region (TSDR) within the murine and human foxp3 locus, with functional 
importance for long-term stability of regulatory T cells126,124. The authors reported an almost 
complete demethylation of this conserved region in natural occurring Treg cells, while TGF-β 
induced Treg showed only weakly demythylated CpG motifs126. Their finding correlated with 
the loss of suppressive capacities and Foxp3 expression when TGF-β was removed from 
these cells, indicating an unstable Treg identity. We therefore purified CD4+CD25+ cells from 
low-dose primed microglia - CD4+ T cell co-cultures and analyzed their DNA methylation 
pattern in the TSDR of foxp3. Compared to CD4+CD25+ nTreg isolated from lymph nodes of 
Bl6/J WT animals, microglia-induced Treg showed a very similar methylation pattern for the 
selected amplicons, indicating a comparably stable phenotype. Notably, the underlying Treg 
purification method based on CD25 expression resulted in CD25+ cells containing a distinct 
proportion of Foxp3- cells (Foxp3+: Foxp3- 1:1). Therefore, nTreg control cells were applied in 
the same ratio. Both samples were found within the same range of methylation in all tested 
CpG motifs, which is approximately 50% (Fig. 3.8). In absolute terms, this implies that all 
Foxp3+ cells in these samples should have been completely unmethylated. Keeping in mind, 
that around two thirds of all Foxp3+ Treg cells, which arise from total CD4+ cells, are de novo 
induced, this would account for a predominantly unmethylated foxp3 locus in microglia-
induced Treg indicating a stable Treg lineage identity. Together with the results from de novo 
induction and proliferation studies, this particular set-up demonstrates the need to analyze 
newly induced and proliferation-derived Foxp3+ Treg from microglia co-cultures as separate 
pools. 
4.3.2 The APC side – Microglia antigen presentation is tightly regulated 
The above discussed differential CD4+ T cell differentiation, cytokine patterns and 
suppressive potential in response to distinct microglia activation prompted us to further study 
microglia phenotypes related to antigen presentation. We hypothesized that the distinct 
levels of stimuli that were applied to activate microglia result in different microglia 
phenotypes, which than directly polarize CD4+ T cell responses. Although the difference of 
respective IFNγ/MOG concentrations, namely 10 U/ml / 1 µg/ml versus 100 U/ml / 10 µg/ml, 
does not seem to be that high, we have to keep in mind that microglia, the immune sentinels 
of the brain, rapidly undergo changes in morphology or function even in response to poor 
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stimuli. How the distinct phenotypes differ in terms of surface molecule expression or 
cytokine production was central in this part of the project. 
The concept of “classical/M1” (IFNγ and LPS mediated) versus “alternative/M2” (IL-4 and IL-
13 mediated) activation of peripheral tissue macrophages has been critically discussed in 
relation to macrophage heterogeneity and differentiation189. In addition, “regulatory” 
macrophages (IFNγ mediated) that suppress T cell proliferation have been described for 
mouse190 and human191. Weber et al. demonstrated that glatiramer acetate treatment 
generated anti-inflammatory type II monocytes that directed differentiation of Th2 and Foxp3+ 
Treg cells106. Whether such classification also exists for microglia and how this would affect 
homeostatic immune responses or responses to brain injury or disease is still not known192. 
To work out which activation-dependent factors influence microglia-mediated T cell 
differentiation, we analyzed microglial proteins providing signal 1-3. 
4.3.3 Signal 1 – TCR-MHCII-Ag complex 
In contrast to professional APC that constitutively express MHC class II, such as B 
lymphocytes, dendritic cells or other cells of the monocyte-macrophage lineage, microglia 
are MHCII negative in their resting state, but can immediately up-regulate MHCII in response 
to injury or disease. The up-regulation of microglial MHCII in response to type II interferon 
(IFNγ) responsive genes has been described in many studies146,154. The observed IFNγ dose-
dependency of MHCII expression (Fig. 3.11) is in line with other studies on per se MHCII-
negative cell types, such as mesenchymal stromal cells193 or epithelial cells194. Most notably, 
raising IFNγ concentrations up to 1000 U/ml did not shift all microglial cells to MHCII+. 
Instead a population of around 40% remained MHCII-, independent of the amount of IFNγ 
applied (data not shown), supporting the idea of microglia functional heterogeneity195. This is 
consistent with other reports stating that even upon full activation, the levels of MHCII and 
costimulatory molecules are much lower than that seen of professional, peripheral APC7. 
Facing the point that adult microglia might show a slightly different responsiveness than that 
of postnatal derived cells196, and that microglial expression of MHCII is known to increase in 
normal aging brains197,198 we contrasted our findings from postnatal microglia with 
experiments performed with microglia directly isolated from adult brains. The observed 
marginal trend in MHCII expression between low- and high-dose stimulated adult microglia 
(Fig. 3.21) is in apparent contrast to the situation in postnatal microglia. However, we did not 
follow these results since the protocol for establishing adult microglia cultures involves the 
use of L929 conditioned media, which contains MCSF and other possibly unknown growth 
factors or cytokines that can potentially influence IFNγ-mediated activation and subsequently 
CD4+ T cell differentiation. 
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In vivo MHCII expressing microglia have been implicated in a number of injury or disease 
settings, such as AD39,40, MS46, CNS injury58,199 or stroke200,201, underlining their potential role 
in the reactivation of CNS infiltrating T cells. The potential of microglia to induce antigen-
specific Foxp3+ regulatory T cells in an MHCII-dependent way has not been studied so far. 
Using Middle Cerebral Artery Occlusion (MCAO) as a model for ischemic stroke our group 
previously demonstrated a strong accumulation of Foxp3+ Treg cells in the ischemic 
hemisphere accompanied by the elevated presence and activation of microglia201. Similarly, 
using ECL, which models a steril, non-inflammatory brain lesion, we could also show an 
increase in the frequency of CNS Foxp3+ Treg cells peaking 14 days after the insult (Stubbe, 
unpublished). Immunohistochemistry identified MHCII+Iba1+ cells in contact or close 
proximity to Foxp3+ Treg cells in the lesioned hemispheres (Stubbe, unpublished). Following 
this first hints, we addressed the question whether CNS MHCII expression is required for 
accumulation of Foxp3+ Tregs cells. When subjecting MHCII-/- mice to ECL, we observed 
CD4+ T cell infiltration on a negligible background level compared to WT mice, without 
significant differences between ipsi- and contralateral hemispheres (Fig. 3.23), suggesting 
that the initial, peripheral T cell activation is fundamental for overall CD4+ T cell invasion into 
the CNS. Therefore we intended to generate bone marrow chimeras with MHCII expression 
restricted to either peripheral or CNS resident APC, subject these mice to ECL and analyze 
the presence of CNS Foxp3+ Treg cells in respective animals (Fig. 3.24, Fig. 3.26). While the 
generation of WT → WT and WT → MHCII-/- chimeras succeeded (Fig. 3.25), MHCII-/- → WT 
chimeric mice developed symptoms attributed to radiation-induced colitis as described by 
Marguerat et al. 8 weeks after reconstitution134. The authors suggested that the gamma-
irradiation induced damage to the intestinal epithelium facilitates the transfer of gut luminal 
antigens to the lamina propria followed by massive lymphocyte activation that is normally 
controlled by regulatory T cells. According to them, reconstituting gamma-irradiated mice 
with cells of hematopoietic origin that lack MHC class II prevents induction and/or activation 
of regulatory T cells and results in fatal colitis134. This view is further supported by other 
studies proving that Treg depletion produces inflammatory bowel disease even without 
irradiation, which likely results from excessive immune responses to commensal bacteria in 
the intestine202. We therefore developed two different strategies to overcome this fatal 
progression; continuous antibiotic treatment to limit bacterial invasion and adoptive Treg 
therapy from congenic animals (Thy1.1) on the day of reconstitution. Independent of the 
treatment applied, all MHCII-/- → WT chimeras succumbed the symptoms of inflammatory 
bowel disease. Since the reasons for symptom development in these mice are largely 
unclear, we can only speculate about failing with the Treg transfer strategy. Possible 
explanations involve small numbers of transferred cells (e.g. 7 x 105 Treg cells/mouse, while 
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a normal mouse contains usually 2.5-3 x 106 Treg115), missing activation/proliferation or the 
need for antigen-specific Tregs locally at the site of inflammation. 
Analyzing numbers and composition of CNS infiltrating leucocytes in WT → WT and 
WT → MHCII-/- chimeras 14 days after ECL surgery revealed that, while overall leucocyte 
infiltration was constant (#CD45high cells, Fig. 3.27 a), the number of CD4+ cells recruited to 
the lesioned site as well as the ratio of Foxp3+ Treg per infiltrated CD45high cell was 
significantly diminished in WT → MHCII-/- mice lacking MHCII specifically in the CNS (Fig. 
3.27 b, d). MHCII expression on CNS resident cells might therefore account for elevated 
Treg cell numbers in vivo. However, a direct comparison of ipsilateral Foxp3+ Treg 
frequencies in the CD4+ compartment turned out to be misleading, since elevated Treg 
frequencies were found in blood and CLN of WT → MHCII-/- chimeras compared to 
WT → WT mice. Because our statement that Foxp3+ regulatory T cells accumulate in the 
ischemic hemisphere after stroke201 and also in the lesioned hemisphere after cortex lesion 
(Stubbe, unpublished) was based on finding significantly increased Foxp3+ frequencies of the 
CD4+ population in the ipsilateral hemispheres compared to contralateral hemispheres, 
peripheral lymphatics and the blood, we were surprised to find that the significant difference 
in Treg frequency between ipsilateral hemisphere and brain draining, cervical lymph nodes 
observed in WT (data not shown) and WT → WT chimeric mice was not detectable in 
WT → MHCII-/- chimeric animals. A possible explanation for the elevated peripheral Tregs 
level might come from studies describing “homeostatic” Treg proliferation, such as 
lymphopenia-induced proliferation when Treg cells are adoptively transferred into 
lymphocyte-deficient hosts203–205. Since homeostatic Treg proliferation is shown to require 
self-MHC class II complexes204, we speculate whether the reconstitution of MHCII-/- mice with 
MHCII potent cells of hematopoetic origin favors the niche for Treg cells. Given the concept 
of a fixed peripheral niche for Treg cells203 that allows them to expand until a certain 
population size independently of naive CD25- T cells in a model of adoptive cell transfer to 
CD3ε–/– recipients206, this set of data suggests the contribution of MHCII expressing non-
hematopoetic cells on regulating Treg homeostasis in the periphery. 
However, there are several points concerning this particular experimental set up that have to 
be critically addressed. Firstly, there is an ongoing debate whether and to what extend 
microglia in the adult brain are replenished by blood circulating progenitor cells207. To control 
for the lack or presence of MHCII expressing newly recruited microglia, markers would have 
been necessary that allow for the discrimination between both populations. Secondly, there 
are hints that gamma irradiation can impair BBB integrity208. This might lead to invasion of 
MHCII potent monocytes and also other immune cells even before subjecting the animals to 
ECL. However, we did not detect significant differences in the number of MHCII expressing 
CD45highCD11b+ CNS infiltrating monocytes/macrophages between WT and MHCII chimeras. 
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In addition, there are a few other CNS resident cell types that can contribute to CNS MHCII 
expression, namely perivascular macrophages, pericytes and astrocytes that have been 
shown to up-regulate MHCII under severe inflammatory conditions209,210. Lastly, MHCII bone 
marrow chimeras represent a complex and artificial model, that on its own needs further 
immunological clarification134 before even more complicated cortex surgeries are evaluated 
based on the current knowledge. In sum, the data generated in MHCII bone marrow chimeric 
mice do not conclusively demonstrate the role of microglial MHCII expression for CNS Treg 
levels in vivo.  
4.3.4 Signal 2 – Co-stimulatory molecules 
The differential regulation of co-stimulatory molecules is an inherent part of the concept of 
macrophage polarization211, but has not been applied so far to more specifically illuminate 
the diverse activation modes of microglial cells in the CNS. 
IFNγ is known to enhance microglial CD40 expression in mice212,213 and men159,214. 
Ponomarev et al. described a two-step activation of microglia during EAE, at the onset and at 
the peak of disease, with only the second activation step being CD40-dependent48. Using 
CD40 bone marrow chimeric mice they demonstrated that CD40 expression by microglia 
contributes to proliferation of encephalitogenic T cells in the CNS and therefore effects 
disease progression. Interestingly, they describe two populations of MHCII expressing 
microglia during the peak of EAE; CD45high activated microglia expressing also high levels of 
co-stimulatory CD40 and CD86, and “resting” CD45low microglia expressing very low levels of 
CD40 and CD86 what they define as bystander activation. As a functional role for bystander 
activated microglia they suggest down-modulation of CNS inflammation by mediating 
tolerance46,48. 
In line with other reports we found low-dose activated microglia to express intermediate 
levels of CD40 and further IFNγ dose-dependent up-regulation of CD40 mRNA (Fig. 3.14)212. 
Since recent studies suggested anti-CD40L mAb treatment to selectively inhibit proliferation 
of effector T cells, but not CD4+CD25+ Treg cells, we performed high-dose co-cultures in the 
presence of anti-CD154129. Notably, we detected around 38% of CD25 expressing CD4+ 
cells, but no increase of Foxp3+ Treg cells in those co-cultures, indicating that CD4+ T cell 
activation was affected, but not impaired and that blocking CD40-CD40L signaling does not 
increase Treg induction mediated by microglial cells. 
Microglia favoring the induction of regulatory T cells revealed an intermediate level of CD86, 
whereas CD80 expression was shown not to be regulated (Fig. 3.14). Performing ECL 
surgery on rats, CD80 and CD86 regulation on microglia in response to mechanically 
induced axonal degeneration was studied by the Bechmann group. They could show that 
after ECL, myelin is presented in a MHCII/CD86 rather than in a MHCII/CD80 context, 
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leading to potentially protective autoimmunity58. This is in line with our in vitro findings 
showing that the different IFNγ/MOG stimulations applied to microglial cells did not lead to 
changes of CD80 mRNA levels. On the contrary, using MCAO to model ischemic stroke 
Gelderblom et al. detected an ipsilateral increase in microglial CD80 expression 3 days after 
the insult215. Their findings were further extended and discussed by Felger et al. who 
reported a strong increase of CD80 relative to CD86 but on brain infiltrating and resident 
DCs147. During severe CNS inflammation, e.g. in MS disease, CD80 seems to be the 
predominant co-stimulatory molecule, detected in lesion sites and cerebrospinal fluid of 
patients216,217, pointing towards a role for CD80 co-stimulation in a rather inflammatory 
situation. These findings illustrate the model dependent activation on brain resident APC and 
the need to carefully distinguish between the different CNS resident APC population. 
Negative co-stimulatory molecules, such as Programmed cell death ligand 1 (PD-L1) or DC-
SIGN/CD209, have also been associated with distinct macrophage activation, e.g. IL-10 
producing regulatory macrophages190,218,219. In addition, a few studies demonstrated 
upregulated PD-L1 expression in vivo in EAE brains and IFNγ-inducible expression on 
microglia220,221. However, these molecules were not found to be regulated on microglial 
mRNA level in response to the established IFNγ/MOG stimulations (data not shown). In sum, 
we could correlate activation-dependent differences on T cell polarization with distinct 
regulation of the co-stimulatory molecules CD40 and CD86 on microglial cells. Reduced 
levels of these co-stimulatory molecules have also been described for anti-inflammatory type 
II monocytes106 and type II-activated macrophages222, both revealing suppressive effects on 
EAE disease. 
4.3.5 Signal 3 – Microenvironment 
Locally secreted cytokines, which reflect the inflammatory or anti-inflammatory micromilieu, 
are thought to be the major determinant of CD4 T cell differentiation and conversion. As T 
cells, macrophages can also polarize to distinct phenotypes (M1 vs. M2a, M2b, M2c) 
secreting discrete sets of cytokines and chemokines and thereby shaping the local cytokine 
milieu. In microglia, Häusler and colleagues showed that IFNγ dose-dependently modulated 
LPS-induced cytokine and chemokine release in vitro, indicating a potent and complex 
immune modulatory effect of IFNγ on microglial cells223. Based on their findings the authors 
speculated about the influence of differential IFNγ stimulation on polarization of Th1/Th2 
responses via microglial cytokine and chemokine synthesis223. 
As a major difference between microglia mediating Foxp3+ Treg induction and those directing 
CD4 T cells towards effector cells, we found immunosuppressive IL-10 to be up-regulated 
exclusively in low-dose primed microglia (Fig. 3.16). This might point towards an alternative 
activation of microglial cells, similar to type II monocytes106 and alternatively activated 
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macrophages224, which are characterized by increased IL-10 production. Because 
macrophages are known to be a source as well as a target for anti-inflammatory IL-10, we 
wanted to further clarify whether the presence of IL-10 during microglia priming has any 
impact on the CD4+ T cell response. Demonstrating that the pre-treatment of microglia with 
high-dose IFNγ/MOG in combination with recombinant IL-10 rescues the regulatory 
phenotype and leads to increased Foxp3+ Treg induction (Fig. 3.17), we speculated that anti-
inflammatory IL-10 modulates IFNγ responsive genes that contribute to microglial antigen 
presentation. As positive control, we analyzed levels of inducible NO synthase (iNOS), which 
is known to be down modulated by IL-10 in macrophages225. Surprisingly, levels of the co-
stimulatory molecules CD40, CD80 and CD86 were unchanged between high-dose and high-
dose + IL-10 stimulated microglia (Fig. 3.18), indicating that the factors or the combination of 
factors making up the regulatory microglia phenotype have not been sufficiently identified. 
Whether tissue macrophages differentiated in a certain microenvironment are terminally 
differentiated or can respond with altering their phenotype to local changes was debated for 
a long time, but recent studies now suggest that macrophage activation states are 
reversible226. We therefore performed experiments where exogenous IL-10 was applied 24 h 
after microglia were stimulated with high-dose and observed a similar rescue of the 
regulatory microglia phenotype (data not shown). This led us to speculate that the 
polarization of microglial cells by high levels of IFNγ is reversible by anti-inflammatory 
signals, such as IL-10 and therefore does not represent and end-stage differentiation. To 
further examine the role of microglial IL-10 on Treg induction we generated primary microglia 
from IL-10 deficient mice and applied them in the co-culture assay. Even though repeated 
many times, we were not able to generate consistent data on microglia mediated Foxp3+ 
Treg induction (data not shown). Notably, cytokine analysis revealed that IL-10KO microglia 
secreted far more TNFα, IL-6, MCP-1 and CXCL1/KC than WT microglia independent from 
the stimulus (data not shown), questioning the suitability of these mice to assess the 
contribution of IL-10 on its own. 
 
Numerous studies argue that IFNγ stimulation favors macrophage differentiation toward an 
M1 profile227. Since microglia populate an immunologically hostile environment, they face 
stimuli clearly distinct from those, confronted by peripheral macrophages. In the healthy CNS 
they constantly monitor their environment and adjacent cells and continuously integrate 
signals from neurons and other glial neighbors228. We therefore assume that microglia are 
able to respond a lot more sensitive to IFNγ danger signals than peripheral, professional 
APC. This is consistent with a study by Hu et al. who demonstrated that different populations 
of monocytes/macrophages have different sensitivities to IFNγ stimulation229. Based on our 
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results we suggest a fine-tuned mechanism by which microglia regulate proteins needed for 
efficient antigen presentation and secretion of cytokines/chemokines depending on their 
activation state and microenvironment (Fig. 4.1). This work supports the view of diverse 
microglia subtypes balancing inflammation through differential effects on effector versus 
regulatory T cells, suggesting an essential role of microglia in regulating immune activation in 
the CNS. 
 
 
Fig. 4.1 Model of inflammatory versus regulatory microglia activation. 
When confronted with IFNγ signals above a certain threshold, microglia aquire an inflammatory phenotype 
characterized by high levels of co-stimulatory molecule expression (CD40, CD86) and low amounts of IL-10, 
and induces effector T cells (Teff) with a pro-inflammatory cytokine profile. A regulatory microglia phenotype 
results from IFNγ danger signals below a certain threshold, is characterized by increased microglial IL-10 
production and low levels CD40 and CD86 and induces CD4+ regulatory T cells (Treg) with suppressive 
functions. 
  
  4 Discussion 
  71 
4.4 Conclusions and Outlook 
It is now evident that CNS resident microglia, rather than simply proceeding from “resting” to 
“activated” states, display various modes of activation with diverse functional outcomes. 
Whether they exert a beneficial or destructive effect on the CNS tissue depends on 
communication signals from neurons, surrounding glial cells or infiltrating immune cells and 
from the micromilieu confronted with14. 
We speculate that microglia, depending on their specific activation, contribute to regulation of 
local CD4+ T cell responses. The here performed in vitro studies revealed that microglia react 
very sensitive to the inflammatory type II interferon IFNγ by modulating molecule levels for 
efficient antigen presentation and levels of secreted cytokines and chemokines. We could 
further show that their distinct activation favored either Treg or effector T cell responses in 
vitro. The Treg development mediated by low-dose IFNγ/MOG stimulated microglia was 
shown to be an interplay of de novo induced Treg and proliferation of pre-existing nTreg cells 
(Fig. 3.6, Fig. 3.7). Previously, our group not only demonstrated reduced EAE severity in 
cortex lesioned mice119, but also the relatively late accumulation of Treg cells in mice 
subjected to cortex lesion (14-30 days after the insult, T. Stubbe, personal communication). 
Whether or not CNS inflammation can be controlled by the presence of Treg cells probably 
will depend on the inflammatory cytokine milieu. We assumed that ECL and also partially 
MCAO model particular weak inflammatory CNS injuries, where potentially low IFNγ levels 
from the initial invasion of T and NK cells give rise to microglia with a regulatory phenotype. 
In these settings, newly recruited T cells, which require continuous antigen-specific re-
activation would then encounter microglia directing them towards tolerance. This might also 
explain the late and long-lasting accumulation of Treg cells after experimental ECL and 
MCAO which is correlated with a significant accumulation of MHCII expressing microglia 
(CD45dimCD11b+ cells) in the ipsilateral hemispheres201. 
Importantly, studies documenting T cell plasticity in the CNS169,176 let us to question final T 
cell commitment after having crossed the barriers, especially in a weak inflammatory model 
such as ECL, and we hypothesized that T cell re-activation can be shaped by microglial 
antigen presentation and the local cytokine milieu. We already demonstrated that infiltrating 
Foxp3+ Treg can proliferate locally in the CNS201 in a model of stroke. Here we show that 
microglia have the potential to mediate de novo induction and proliferation of Foxp3+ Treg. 
Therefore, subimmunogenic activation of microglia by low-level IFNγ could be a possible 
regulatory mechanism that limits the expansion of autoantigen-specific effector T cells in the 
CNS. Such mechanisms could explain why brain injury, despite the presence of myelin-
specific T cells in injured regions, does not lead to destructive autoimmunity. 
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The control of microglial activation under pathological conditions seems to be a promising 
therapeutic target for limiting CNS inflammation. The fact that microglia show distinct, 
activation-dependent phenotypes leads to the question how we can take advantage of 
neuroprotective microglial activation, without promoting neurodestructive processes. For MS 
disease, where the re-activation of infiltrating T cells behind the brain barriers is a critical 
point in the initial phase of disease, the strength of re-activation has been suggested to 
determine the degree of subsequent parenchymal inflammation15,230. Given the fact that the 
strength of re-activation depends on both the affinity of the particular TCR for its cognate 
antigen and on the number of specific antigen-MHC complexes available on the surface of 
APC15, the fine-tuning of regulating antigen presentation is of particular importance for cells 
that are per se MHCII negative. Since the co-stimulatory pathways have recently turned out 
to be of bilateral signaling influencing also the phenotype of the APC218, much more effort is 
needed to better understand the interaction of microglia and the very first infiltrating T cells. 
Furthermore, regulatory microglia need to be characterized in more detail with focusing on 
the molecular switches and signaling pathways that drive their phenotypic conversion. 
Recently, the Notch pathway was identified to determine M1 versus M2 macrophage 
polarization231. Our IL-10 rescue studies provide first hints, that the molecular factor/factors 
that allows them to induce Foxp3+ Treg cells is/are somehow influenced by IL-10 signaling. 
How exactly IL-10 modifies IFNγ induced activation of microglia should be analyzed for a 
wider spectrum of genes and/or proteins, e.g. by comparing low-dose, high-dose and high-
dose+ IL-10 activated microglia on a microarray. 
Of overall importance is the identification of a microglia specific marker that allows the clear 
differentiation between newly recruited monocytes/macrophages and CNS resident microglia 
for flow cytometry and immunohistochemistry. In addition, in vivo approaches with the aim to 
identify location, persistence and motility of regulatory microglia would deepen our 
understanding of local CNS immune regulation. 
Going back to the initial experiments of our group, where ECL-lesioned mice were subjected 
to EAE immunization and showed reduced disease severity compared to sham operated 
animals119, further studies could use conditional Foxp3 knockout mice to prevent 
accumulation of Foxp3+ Treg after ECL and immunize the mice as soon as peripheral Treg 
levels are restored, to evaluate the functional relevance of CNS Treg cells. 
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